Academic peer-reviewed journal articles which include Cancer Trials Ireland Members as co-authors
Peer Reviewed Journals
Study Number: Short Name |
2024 Journal Publications |
| 22-01: SHAMROCK | Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study). Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, McLoughlin O, Teiserskiene A, Power C, O’Shea AM, Greally M, Morris PG, Duke D, Hill ADK, Hennessy BT.Future Oncol. 2024 Jan 20(1):5-16 PMID: 37916267 |
| 12-43: TRIO 022/ PALOMA-2 | The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. Future Oncol. 2024 Jan;20(1):5-16. Review PMID: 37916267 |
| 22-01: SHAMROCK | Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study). Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, McLoughlin O, Teiserskiene A, Power C, O’Shea AM, Greally M, Morris PG, Duke D, Hill ADK, Hennessy BT.BMC Cancer. 2024 Jan 24(1):91. PMID: 38233810 |
| 14-11: PENELOPE-B | Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study. García-Sáenz JA, Marmé F, Untch M, Bonnefoi H, Kim SB, Bear H, McCarthy N, Gelmon K, Martin M, Kelly CM, Reimer T, Toi M, Law E, Bhattacharyya H, Gnant M, Makris A, Seiler S, Burchardi N, Nekljudova V, Loibl S, Rugo HS. Eur J Cancer. 2024 Jan 196:113420 PMID: 38000218 |
| 12-43: TRIO 022/Paloma-2 | Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS.J Clin Oncol. 2024 Mar 20;42(9):994-1000. PMID: 38252901 |
| 06-32: NSABP B42 | Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial. Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE Jr, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N. Clin Cancer Res. 2024 May 30(9):1984-1991 PMID: 38376912 |
| 14-11: PENELOPE-B | Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B. Marme F, Martin M, Untch M, Thode C, Bonnefoi H, Kim SB, Bear H, McCarthy N, Gelmon K, García-Sáenz JA, Kelly CM, Reimer T, Valota O, Toi M, Rugo HS, Gnant M, Makris A, Bassy M, Zhang Z, Furlanetto J, Nekljudova V, Loibl SESMO Open. 2024 Jun 9(6):103466 PMID: 38838498 |
| 16-20: IBCSG 48-14 POSITIVE | Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy. Azim HA Jr, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA. J Clin Oncol. 2024 Aug 42(23):2822-2832 PMID: 38810178 |
| 06-32: NSABP B42 | Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. Rastogi P, Bandos H, Lucas PC, van ‘t Veer LJ, Wei JJ, Geyer CE Jr, Fehrenbacher L, Chia SKL, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Menicucci AR, Audeh MW, Wolmark N, Mamounas EP. J Clin Oncol. 2024 Oct 42(30):3561-3569 PMID: 39047219 |
| 21-05: DESTINY Breast 12 | Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, Kurzeder C, Higgins MJ, Connolly RM, Baron-Hay S, Gión M, Guarneri V, Bianchini G, Wildiers H, Escrivá-de-Romaní S, Prahladan M, Bridge H, Kuptsova-Clarkson N, Scotto N, Verma S, Lin NU; DESTINY-Breast12 study group. Nat Med. 2024 Sep 13. PMID: 39271844 Online ahead of print. |
| 15-17: PALLAS | Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109). Nader-Marta G, Singer C, Hlauschek D, DeMichele A, Tarantino P, de Azambuja E, Pfeiler G, Martin M, Balko JM, Nowecki Z, Balic M, Brufsky AM, Chan A, Morris PG, Haddad T, Loibl S, Liu Y, Soelkner L, Fesl C, Mayer EL, Gnant M; PALLAS groups and investigators. Breast Cancer Res. 2024 Oct 26(1):140. PMID: 39375745 |
| 12-01: RX PONDER/SWOG S1007 | Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype DX® testing in early-stage, 1-3 lymph node-positive, oestrogen receptor-positive, HER2-negative, breast cancer. Browne IM, McLaughlin RA, Weadick CS, O’Sullivan S, McSorley LM, Hadi DK, Millen SJ, Higgins MJ, Crown JP, Prichard RS, McCartan DP, Hill AD, Connolly RM, Noonan SA, O’Mahony D, Murray C, O’Hanlon-Brown C, Hennessy BT, Quinn CM, Kelly CM, O’Reilly S, Morris PG, Walshe JM. Breast Cancer Res Treat. 2024 Oct PMID: 39365509 |
| 07-02: ALTTO | Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]. de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-Abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A. ESMO Open. 2024 Nov 9(11):103938 PMID: 39418883. |
| 23-05: Metastatic Breast Cancer Survey | A patient-led survey on information and communication needs of patients with metastatic breast cancer in Ireland and Northern Ireland (CTRIAL-IE 23-05). Gaynor S, O’Meara Y, Mulvaney E, Keogh RJ, Weadick CS, Duane FJ, Mc Brien A, Greally H, O’Leary MJ, Teiserskyte I, Beristain I, Marron J, Mulroe E, Donachie V, Mc Loughlin S, O’Reilly S. Breast. 2024 Nov 20;79:103837. PMID: 39591880 Online ahead of print. |
| 15-49: NeoTRIP | The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer. Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G. . Clin Cancer Res. 2024 Nov 30(21):4900-4909 PMID: 39308141. |
| 10-14: Neo-AEGIS | Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial – Authors’ reply. Reynolds JV, Donachie V, Marron J, Shevlin A; Neo-AEGIS Investigators and Trial Group. Lancet Gastroenterol Hepatol. 2024 Feb 9(2):104-105 PMID: 38215774. |
| 12-38: TRI-LARC | Quality of Life Analysis of a Phase II randomised controlled trial comparing 3D-Conformal Radiotherapy and Intensity Modulated Radiotherapy in Locally Advanced Rectal Cancer (TRI-LARC). Geary RI, Gillham C, McVey G, Armstrong J, Cunningham M, Rangaswamy G, Sharma D, Wa Ilace N, Skorou C, Dunee M, Mahon M, Bradshaw S, O’Sullivsn L, Marron J, Parker I, Shannon AM, McDermott R, Toomey S, Hennessy BT, O’Neill B. Clin Oncol. 2024 Nov 103695 in press. |
| 17-30: IRONMAN | Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer. Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, Bjartell A, Russnes KM, Heath EI, Pomerantz MM, Henegan JC, Hyslop T, Esteban E, Omlin A, McDermott R, Fay AP, Popoola AA, Ragin C, Nowak J, Gerke T, Kantoff PW, George DJ, Penney KL, Mucci LA; IRONMAN Registry. . Cancer Epidemiol Biomarkers Prev. 2024 Mar 33(3):419-425 PMID: 38189661. |
| 24-22 De-Escalate | EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors. Grisay G , Turco F, Litiere S, Fournier B, Patrikidou A, Gallardo E, McDermott R, Alanya A, Gillessen S, Tombal B. Front Oncol. 2024 May 8:14:1391825 PMID: 38779087 |
| 12-16: AC-ANGIOPREDICT | Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients. Venken T, Miller IS, Arijs I, Thomas V, Barat A, Betge J, Zhan T, Gaiser T, Ebert MP, O’Farrell AC, Prehn J, Klinger R, O’Connor DP, Moulton B, Murphy V, Serna G, Nuciforo PG, McDermott R, Bird B, Leonard G, Grogan L, Horgan A, Schulte N, Moehler M, Lambrechts D, Byrne AT. . NPJ Genom Med. 2024 May 9(1):33 PMID: 38811554 |
| 15-46: PACE-B | Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer. Shore N, Carles J, McDermott R, Agarwal N, Tombal B. Front Med (Lausanne). 2024 Oct 24:11:1460212 PMID: 39526247 |
| 16-21 PACE III | EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors. Grisay G , Turco F, Litiere S, Fournier B, Patrikidou A, Gallardo E, McDermott R, Alanya A, Gillessen S, Tombal B. Front Oncol. 2024 May 8:14:1391825 PMID: 38779087 |
| 13-09: PEACE-1 | Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K; PEACE-1 investigators. . Lancet. 2024 Nov 23;404(10467):2065-2076. PMID: 39580202 |
| 14-02: SHAPE trial | Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjilfsdottir B, Kim J, Gleeson N, Brotto L, Tu D, Shepherd LE, et al., for the CX.5 SHAPE investigators N Engl J Med. 2024 Feb 390:819-829 PMID: 38416430. |
| 10-12: ANZGOG-0701 Symptom Benefit Study | EORTC 2238 “Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. Roncolato F, King MT, O’Connell RL, Lee YC, Joly F, Hilpert F, Lanceley A, Yoshida Y, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Kaminsky MC, Stockler MR, Friedlander M. Gynecol Oncol. 2024 Jun 185:128-137 PMID: 38412736 |
| 16-04: PRIMA | Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer. Monk BJ, Romero I, Graybill W, Churruca C, O’Malley DM, Knudsen AØ, Yap OWS, Baurain JF, Rose PG, Denys H, Ghamande S, Pisano C, Fabbro M, Braicu EI, Calvert PM, Amit A, Prendergast E, Taylor A, Kheibarshekan L, Zhang ZY, Zajic S, Jewell RC, Gupta D, González-Martín A. . Clin Ther. 2024 Aug 46(8):612-621 PMID: 39019698 |
| 20-06: SORAYA | Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, van Gorp T, Konner JA, Romeo Marin M, Harter P, Murphy C, Wang Y, Esteves B, Method M, Matulonis U. .Int J Gynecol Cancer. 2024 Aug 5;34(8):1119-1125. PMID: 38858103 . |
| 14-02: SHAPE trial | Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy. Ferguson SE, Brotto LA, Kwon J, Samouelian V, Ferron G, Maulard A, Kroon C, Driel WV, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjolfsdottir B, Kim JW, Gleeson N, Tu D, Shepherd L, Plante M. .J Clin Oncol. 2024 Oct 1:JCO2400440. PMID: 39353164. Online ahead of print. |
| 14-02: SHAPE trial | Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial. Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouëlian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, de Kroon C, van Driel W, Mahner S, Hanker L, Goffin F, Berger R, Eyjólfsdóttir B, Kim JW, Brotto LA, Pataky R, Yeung SST, Chan KKW, Cheung MC, Ubi J, Tu D, Shepherd LE, Plante M. .J Gynecol Oncol. 2024 Nov;35(6):e117. PMID: 39453395 |
| Non-CTRIAL: PICCOLO Trial | The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial. Secord AA, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Pérez MJR, Bonaventura A, Diver EJ, Ayuk SA, Wang Y, Corr BR, Salutari V.Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. PMID: 39617145. Online ahead of print. |
| Safety Data Analysis for Mirvetumab (various trials) | Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O’Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Gynecol Oncol. 2024 Oct 25;191:249-258. PMID: 39461270. Online ahead of print. |
| Dealing with digital paralysis: Surviving a cyberattack in a National Cancer center. Keogh RJ, Harvey H, Brady C, Hassett E, Costelloe SJ, O’Sullivan MJ, Twomey M, O’Leary MJ, Cahill MR, O’Riordan A, Joyce CM, Moloney G, Flavin A, M Bambury R, Murray D, Bennett K, Mullooly M, O’Reilly S. J Cancer Policy. 2024 Mar;39:100466. PMID: 38176467 | |
| Sustainability: a multifaceted important aspect of cancer care. O’Reilly S, Weadick CS, Keogh RJ. BJC Rep 2024 Mar 2(1):19 PMID: 39516350 | |
| Climate change advocacy and cancer clinical trial organisations. Oo NM, Weadick CS, Murphy L, O’Reilly S. BJC Rep 2024 Jul 2(1):49 PMID: 39516678 | |
| Optimising oncology drug expenditure in Ireland. Kieran R, Hennessy M, Coakley K, O’Sullivan H, Cronin T, Lynch D, Mulroe E, Cooke K, Collins D, O’Reilly S. Ir J Med Sci. 2024 Aug;193(4):1735-1747. PMID: 38568369 | |
| What is the carbon footprint of academic clinical trials? A study of hotspots in 10 trials. Griffiths J, Adshead F, Al-Shahi Salman R, Anderson C, Bedson E, Bliss J, Boshoff A, Chen X, Cranley D, Doran P, Dunne F, Gamble C, Gillies K, Hood K, Kavanagh C, Malone J, McGregor N, McNamara C, Midha E, Moore K, Murphy L, Newman C, O’Reilly S, Perkins AM, Pett S, Sydes MR, Whitty L, You F, Fox L, Williamson PR. BMJ Open 2024 Sep Vol 14 (10) PMID: 39414270 | |
| Why We Should, and How We Can, Reduce the Climate Toxicity of Cancer Care. Lynch E, Bredin P, Weadick CS, Dorney N, Van Leeuwen RWF, O’Reilly S.JCO Oncol Pract 2024 Nov PMID: 39486013 | |
Study Number: Short Name |
2023 Journal Publications |
| 16-20: POSITIVE | Partridge, A. H., S. M. Niman, M. Ruggeri, F. A. Peccatori, H. A. Azim Jr, M. Colleoni, C. Saura, C. Shimizu, A. B. Sætersdal, J. R. Kroep, A. Mailliez, E. Warner, V. F. Borges, F. Amant, A. Gombos, A. Kataoka, C. Rousset-Jablonski, S. Borstnar, J. Takei, J. E. Lee, J. M. Walshe, M. Ruíz-Borrego, H. Moore, C. Saunders, V. Bjelic-Radisic, S. Susnjar, F. Cardoso, K. L. Smith, T. Ferreiro, K. Ribi, K. Ruddy, R. Kammler, S. El-Abed, G. Viale, M. Piccart, L. A. Korde, A. Goldhirsch, R. D. Gelber, O. Pagani, International Breast Cancer Study Group; POSITIVE Trial Collaborators (2023) “Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer” N Engl J Med 388(18):1645-1656. PMID: 37133584 |
| 15-49: NeoTRIP | Wang, X. Q., E. Danenberg, C. Huang, D. Egle, M. Callari, B. Bermejo, M. Dugo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, S. Russo, E. M. Ciruelos, R. Greil, B. Győrffy, V. Semiglazov, M. Colleoni, C. M. Kelly, G. Mariani, L. Del Mastro, O. Biasi, R. S. Seitz, P. Valagussa, G. Viale, L. Gianni, G. Bianchini, H. R. Ali (2023) “Spatial predictors of immunotherapy response in triple-negative breast cancer” Nature 621(7980):868-876 PMID: 37674077 |
| 10-11: Circulating miRNAs | Davey, M. G., R. Abbas, E. P. Kerin, M. C. Casey, A. McGuire, R. M. Waldron, H. M. Heneghan, J. Newell, A. M. McDermott, M. M. Keane, A. J. Lowery, N. Miller, M. J. Kerin (2023) “Circulating microRNAs can predict chemotherapy-induced toxicities in patients being treated for primary breast cancer” Breast Cancer Res Treat 202(1):73-81 PMID: 37540289 |
| 06-32: NSABP B42 | Mamounas, E. P., H. Bandos, P. Rastogi, B. C. Lembersky , J. Jeong, C. E. Geyer, L. Fehrenbacher, S. K. Chia, A. M. Brufsky, J. M. Walshe, G. S. Soori, S. R. Dakhil, J. L. Wade, E. C. McCarron, S. M. Swain, N. Wolmark (2023) “Ten-year Update: NRG Oncology/NSABP B-42 Randomized Trial: Extended Letrozole Therapy in Early-stage Breast Cancer” J Natl Cancer Inst 115(11):1302-1309 PMID: 37184928 |
| 15-16: FLIPPER | Tibau, A., M. T. Martínez, M. Ramos, L. D. Cruz-Merino, A. Santaballa, M. O’Connor, N. Martínez-Jañez, F. Moreno, I. Fernández, J. A. Virizuela, J. Alarcón, J. de. Haba-Rodríguez, P. Sánchez-Rovira, C. R. Albacar, C. B. Muiño, C. Kelly, M. Casas, S. Bezares, L. Rosell, J. Albanell (2023) “Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial” Ther Adv Med Oncol 15:17588359221148921 PMID: 36743520 |
| 10-05: TCHL | Gaynor, N., A. Blanco, S. F. Madden, B. Moran, J. M. Fletcher, D. Kaukonen, J. S. Ramírez, A. J. Eustace, M. S. McDermott, A. Canonici, S. Toomey, A. Teiserskiene, B. T. Hennessy, N. O’Donovan, J. Crown, D. M. Collins (2023) “Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy” Br J Cancer 129(6):1022-1031 PMID: 37507543 |
| 11-23: APHINITY / BIG 4-11 | Azambuja, E de., E. Agostinetto, M. Procter, D. Eiger, N. Pondé, S. Guillaume, D. Parlier, M. Lambertini, A. Desmet, C. Caballero, C. Aguila, G. Jerusalem, J. M. Walshe, E. Frank, J. Bines, S. Loibl, M. Piccart-Gebhart, M. S. Ewer, S. Dent, C. Plummer, T. Suter, APHINITY Steering Committee and Investigators (2023) “Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial” ESMO Open 8(1):100772 PMID: 36681013 |
| 15-17: PALLAS | Pfeiler, G., D. Hlauschek, E. L. Mayer, C. Deutschmann, S. Kacerovsky-Strobl, M. Martin, J. L. Meisel, N. Zdenkowski, S. Loibl, M. Balic, H. Park, A. Prat, C. Isaacs, E. Bajetta, J. M. Balko, M. Bellet-Ezquerra, J. Bliss, H. Burstein, F. Cardoso, H. Fohler, T. Foukakis, K. A. Gelmon, M. Goetz, T. C. Haddad, H. Iwata, J. Jassem, S. Lee, B. Linderholm, M. Los, E. P. Mamounas, K. D. Miller, P. G. Morris, E. Munzone, E. N. Gal-Yam, A. Ring, L. Shepherd, C. Singer, C. Thomssen, L. Tseng, P. Valagussa, E. P. Winer, A. C. Wolff, G. Zoppoli , J. Machacek-Link, C. Schurmans, X. Huang, E. Gauthier, C. Fesl, A. C. Dueck, A. DeMichele, M. Gnant, PALLAS Groups and Investigators (2023) “Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial” J Clin Onco 41(33):5118-5130 PMID: 37556775 |
| Punt, C. J. A., V. Heinemann, T. Maughan, C. Cremolini, E. Van. Cutsem, R. McDermott, G. Bodoky, T. André, P. Osterlund, A. J. Teske, P. Pfeiffer (2023) “Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer” ESMO Open 8(2):101199 PMID: 37018874 | |
| 16-20: 10-14: Neo-AEGIS | Reynolds, J. V., S. R. Preston, B. O’Neill, M. A. Lowery, L. Baeksgaard, T. Crosby, M. Cunningham, S. Cuffe, G. O. Griffiths, I. Parker, S. L. Risumlund, R. Roy, S. Falk, G. B. Hanna, F. R. Bartlett, A. Alvarez-Iglesias, M. P. Achiam, M. Nilsson, G. Piessen, N. Ravi, D. O’Toole, C. Johnston, R. S. McDermott, R. C. Turkington, S. Wahed, S. Sothi, H. Ford, M. S. Wadley, D. Power, Neo-AEGIS Investigators and Trial Group (2023) “Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial” Lancet Gastroenterol Hepatol 8(11):1015-1027 PMID: 37734399 |
| 16-20: 15-46: PACE-B | Van As, N., A. Tree, J. Patel, P. Ostler, H. Van Der Voet, D.A. Loblaw, W. Chu, D. Ford, S. Tolan, S. Jain, J.G. Armstrong, P. Camilleri, K. Kancherla, J. Frew, A. Chan, O. Naismith, G. Manning, S. Brown, C. Griffin, E. Hall (2023) “5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer” International Journal of Radiation Oncology, Biology, Physics VOLUME 117, ISSUE 4, E2-E3 |
| 16-20: 08-17: IMRT Prostate | Nicholson, J., B. D. O’Neill, P. Thirion, M. Cunningham, G. McVey, J. Coffey, A. M. Mihai, P. J. Kelly, N. Elbeltagi, M. Dunne, E. Noone, I. Parker, A. M. Shannon, M. McCague, A. Alvarez-Iglesias, H. Kelly, R. O’Donovan, D. Hajdaraj, G. Lawler, J. G. Armstrong (2023) “A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0M0 Prostate Cancer” International Journal of Radiation Oncology, Biology, Physics VOLUME 117, ISSUE 2, SUPPLEMENT , E422 |
| 16-20: 14-06: ENZAMET | Sweeney, C. J, A. J. Martin, M. R. Stockler, S. Begbie, L. Cheung, K. N. Chi, S. Chowdhury, M. Frydenberg, L. G. Horvath, A. M. Joshua, N. J. Lawrence, G. Marx, J. McCaffrey, R. McDermott, M. McJannett, S. A. North, F. Parnis, W. Parulekar, D. W. Pook, M. N. Reaume, S. K. Sandhu, A. Tan, T. H. Tan, A. Thomson, F. Vera-Badillo, S. G. Williams, D. Winter, S. Yip, A. Y. Zhang, R. R. Zielinski, I. D. Davis, ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2023) “Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial” Lancet Oncol 24(4):323-334. PMID: 36990608 |
| 16-20: 16-70: BMS CA209-274 / CheckMate 274 | Bajorin, D. F., J. A. Witjes, J. E Gschwend, M. Schenker, B. P. Valderrama, Y. Tomita, A. Bamias, T. Lebret, S. F. Shariat, S. Park, D. Ye, M. Agerbaek, D. Enting, R. McDermott, P. Gajate, A. Peer, M. I. Milowsky, A. Nosov, J. N. Antonio Jr, K. Tupikowski, L. Toms, B. S. Fischer, A. Qureshi, S. Collette, K. Unsal-Kacmaz, E. Broughton, D. Zardavas, H. B. Koon, M. D. Galsky (2023) “Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary” Future Oncol 19(6):413-426 PMID: 36919916 |
| 15-21: The ExPeCT Trial | Sheill, G., L. Brady, B. Hayes, A. Baird, E. Guinan, R. Vishwakarma, C. Brophy, T. Vlajnic, O. Casey, V. Murphy, J. Greene, E. Allott, J. Hussey, F. Cahill, M. Van. Hemelrijck, N. Peat, L. Mucci, M. Cunningham, L. Grogan, T. Lynch, R. P. Manecksha, J. McCaffrey, D. O’Donnell, O. Sheils, J. O’Leary, S. Rudman, R. McDermott, S. Finn (2023) “ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancer” Support Care Cancer 31(5):292 PMID: 37086362 |
| 20-19: MK7339-010 / KEYLINK-010 | Antonarakis, E. S., S. H. Park, J. C. Goh, S. J. Shin, J. L. Lee, N. Mehra, R. McDermott, N. Sala-Gonzalez, P. C. Fong, R. Greil, M. Retz, J. P. Sade, P. Yanez, Y. Huang, S. D. Begbie, R. A. Gafanov, M. D. Santis, E. Rosenbaum, M. P. Kolinsky, F. Rey, K. Chiu, G. Roubaud, G. Kramer, M. Sumitomo, F. Massari, H. Suzuki, P. Qiu, J. Zhang, J. Kim, C. H. Poehlein, E. Y. Yu (2023) “Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial” J Clin Oncol 41(22):3839-3850 PMID: 37290035 |
| 20-20: TRITON-3 | Fizazi, K., J. M. Piulats, M. N. Reaume, P. Ostler, R. McDermott, J. R. Gingerich, E. Pintus, S. S. Sridhar, R. M. Bambury, U. Emmenegger, H. Lindberg, D. Morris, F. Nolè, J. Staffurth, C. Redfern, M. I. Sáez, W. Abida, G. Daugaard, A. Heidenreich, L. Kriege, B. Sautois, A. Loehr, D. Despain, C. A. Heyes, S. P. Watkins, S. Chowdhury, C. J. Ryan, A. H. Bryce; TRITON3 Investigators (2023)” Rucaparib or Physician’s Choice in Metastatic Prostate Cancer” N Engl J Med 388(8):719-732. PMID: 36795891 |
| 15-46: PACE-B (Newspaper Article) | J.G. Armstrong (2023) “Prostate cancer breakthrough to bring ‘massive advantages’ for patients” Irish Times – Prostate cancer |
| 09-06: Endometrial IMRT | Nugent, K., D. Browne, M. Dunne, L. O’Sullivan, A. M. Shannon, D. Sharma, S. Bradshaw, O. McArdle, O. Salib, N. Lavan, C. Gillham (2023) “Prospective randomised phase II trial evaluating adjuvant pelvic radiotherapy using either IMRT or 3-Dimensional planning for endometrial cancer” Acta Oncol 62(8):907-914 PMID: 37493622 |
| 16-04: PRIMA | Mirza, M. R., A. González-Martín, W. S. Graybill, D. M. O’Malley, L. Gaba, O. W. S. Yap, E. M. Guerra, P. G. Rose, J. Baurain, S. A. Ghamande, H. Denys, E. Prendergast, C. Pisano, P. Follana, K. Baumann, P. M. Calvert, J. Korach, Y. Li, I. A. Malinowska, D. Gupta, B. J. Monk (2023) “Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial” Cancer 129(12):1846-1855 PMID: 37060236 |
| 18-35: ENGOT cx8/GCT1015-05 | Vergote, I., E. V. Nieuwenhuysen, R. E. O’Cearbhaill, A. Westermann, D. Lorusso, S. Ghamande, D. C. Collins, S. Banerjee, C. A. Mathews, C. Gennigens, D. Cibula, K. S. Tewari, K. Madsen, F. Köse, A. L. Jackson, I. A. Boere, G. Scambia, L. M. Randall, A. Sadozye, J. Baurain, E. Gort, M. Zikán, H. G. Denys, N. Ottevanger, F. Forget, C. M. Andreassen, L. Eaton, M. J. Chisamore, L. Vi. Nicacio, I. Soumaoro, B. J. Monk (2023) “Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study” J Clin Oncol 41(36):5536-5549 PMiD: 37651655 |
| 15-39: D5160C00022/ASTRIS: | Cheema, P., B. C. Cho, H. Freitas, M. Provencio, Y. M. Chen, S. Kim, Y. Wu, A. Passaro, C. Martin, M. Tiseo, G. Chang, K. Park, B. Solomon, O. Burghuber, J. Laskin, Z. Wang, S. Y. Lee, Y. Hu, J. Vansteenkiste, H. Zhang, E. Hanrahan, T. Geldart, R. Taylor, L. Servidio, J. Li, F. de Marinis (2023) “A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data” Future Oncol 19(1):61-75 PMID: 36656302 |
| Keogh,, R. J., M. P. Barr, A. Keogh, D. McMahon, A. Baird, S. Cotter, D. Breen, G. J. Fitzmaurice, D. Fitzpatrick, C. O’Brien, S. P. Finn, J. Naidoo (2023) “Lung Cancer in the Republic of Ireland” J Thorac Oncol 18(7):851-857 PMID: 37348994 | |
| Book Chapter | O’Reilly, D., A. Botticella, S. Barry, S. Cotter, J. S. Donington, C. Le Pechoux, J. Naidoo (2023) “Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More?” Am Soc Clin Oncol Educ Book 43:e389950 PMID: 37220324 |
| 16-60: CLL13 | Fürstenau, M., Y. J. Thus, S. Robrecht, C. H. M. Mellink, A. Kevie-Kersemaekers, J. Dubois, J. Tresckow, M. Patz, M. Gregor, P. Thornton, P. B. Staber, T. Tadmor, M. Levin, C. da Cunha-Bang, C. Schneider, C. B. Poulsen, T. Illmer, B. Schöttker, A. Janssens, I. Christiansen, T. Nösslinger, M. Baumann, H. Hebart, T. Gaska, J. C. Regelink, E. C. Dompeling, V. Lindström, G. Juliusson, A. Widmer, J. Goede, N. Goldschmidt, F. Simon, N. De Silva, A. Fink, K. Fischer, C. Wendtner, M. Ritge, M. Brüggemann, E. Tausch, M. Spaargaren, E. Eldering, S. Stilgenbauer, C. U. Niemann, M. Hallek, B. Eichhorst, K. Kreuzer , A. P. Kater (2023) “High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations” Blood 142(5):446-459 PMID: 37172204 |
| Harvey, H., H. Carroll, V. Murphy, J. Ballot, M. O’Grady, D. O’Hare, G. Lawler, E. Bennett, M. Connolly, E. Noone, M. G. Kelly, A. Bazin, A. Daly, E. Mulroe, R. McDermott, S. O’Reilly (2023) “The Impact of a National Cyberattack Affecting Clinical Trials: The Cancer Trials Ireland Experience” JCO Clin Cancer Inform 7:e2200149 PMID: 37053539 | |
| Weadick,, C. S., R. J. Keogh, H. K. Carroll, S. Boldrin, E. Mulroe, L. Murphy, B. Sheils, A. Barry, S. O’Reilly (2023) “Climate toxicity: An increasingly relevant clinical issue in Cancer Care” J Cancer Policy 35:100410 PMID: 36773799 | |
| Kumar, S., L. Shen, D. S. Hong, R. McDermott, V. L. Keedy, M. Casanova, G. D. Demetri, A. Dowlati, S. G. Melcón, U. N. Lassen, S. Leyvraz, T. Liu, V. Moreno, J. Patel, T. Patil, A. B. Mallick, N. Sousa, M. Tahara, D. S. Ziegler, R. Norenberg, P. Arvis, N. Brega, A. Drilon, D. S W. Tan (2023) “Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas” Cancer 129(23):3772-3782 PMID: 37769113 | |
| Lawler, M., R. Sullivan, G. K. Abou-Alfa, K. McCloskey, D. Keatley, J. Feighan, W. Dahut, E. Mulroe, R. Ladner, M. Genead, M. Lowery, J. L. Gulley, C. J. Scott, D. B. Longley, A. Culhane, W. M. Gallagher, N. Orr, S. J. Chanock, S. Gopal (2023) “Health diplomacy in action: The cancer legacy of the Good Friday Agreement” J Cancer Policy 38:100448 PMID: 37839622 | |
| O’Reilly, S., H. K. Carroll, D. Murray, L. Burke, T. McCarthy, R. O’Connor , C. Kilty, S. Lynch, J. Feighan, M. Cloherty, P. Fitzpatrick, K. Falvey, V. Murphy, M. J. O’Leary, S. Gregg, L. Young, E. McAuliffe, J. Hegarty, A. Gavin, M. Lawler, P. Kavanagh, S. Spillane, T. McWade, M. Heffron, K. Ryan, P. Kelly, A. Murphy, M. Corrigan, H. P. Redmond, P. Redmond, P. Walsh, P. Tierney, M. Zhang, K. Bennett, M. Mullooly (2023) “Impact of the COVID-19 pandemic on cancer care in Ireland – Perspectives from a COVID-19 and Cancer Working Group” J Cancer Policy 36:100414. PMID: 36841473 | |
| Briggs, S. EW., I. Turgeman, S. O’Reilly, C. S. Weadick, L. Murphy, R. B. Guzman, R. Chuter, (2023) “Climate change: The problems and potential solutions in oncology” Cancer Control | |
Study Number: Short Name |
2022 Journal Publications |
| 15-42: LOXO 101 study | Waguespack, S. G., A. Drilon, J. J. Lin, M. S. Brose, R. McDermott, M. Almubarak, J. Bauman, M. Casanova, A. Krishnamurthy, S. Kummar, S. Leyvraz, D. Y. Oh, K. Park, D. Sohal, E. Sherman, R. Norenberg, J. D. Silvertown, N. Brega, D. S. Hong & M. E. Cabanillas (2022). “Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.” Eur J Endocrinol, 186(6): 631-643. PMID: 35333737 |
| 15-42: LOXO 101 study | Le, X., C. Baik, J. Bauman, J. Gilbert, M. S. Brose, J. E. Grilley-Olson, T. Patil, R. McDermott, L. Raez, J. M. Johnson, L. Shen, M. Tahara, A. L. Ho, R. Norenberg, L. Dima, N. Brega, A. Drilon, D. S. Hong (2022).“Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers” Oncologist., oyac080. PMID: 35536733. |
| 15-16: FLIPPER | Albanell, J., M. T. Martínez, M. Ramos, M. O’Connor, L. de la Cruz-Merino, A. Santaballa, N. Martínez- Jañez, F. Moreno, I. Fernández, J. Alarcón, J. A. Virizuela, J. de la Haba-Rodríguez, P. Sánchez-Rovira, L. González-Cortijo, M. Margelí, A. Sánchez-Muñoz, A. Antón, M. Casas, S. Bezares and F. Rojo (2022). “Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER).” Eur J Cancer, 161: 26-37. PMID: 34902765. |
| 10-06: TROG DCIS | Chua, B. H., E. K. Link, I. H Kunkler, T. J. Whelan, A. H. Westenberg, G. Gruber, G. Bryant, V. Ahern, K. Purohit, P. H. Graham, M. Akra, O. McArdle, P. Brien, J. A. Harvey, C. Kirkove, J. H. Maduro, I. D. Campbell, G. P. Delaney, J. D. Martin, T. T. Vu, T. M. Muanza, A. Neal, I. A. Olivotto, BIG 3–07/TROG 07.01 trial investigators (2022). “Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.” Lancet 400(10350):431-440. PMID: 35934006. |
| 10-11: Circulating miRNAs | Davey, M. G., M. C. Casey, A. McGuire, R. M. Waldron, M. Paganga, E. Holian, J. Newell, H. M. Heneghan, A. M. McDermott, M. M. Keane, A. J. Lowery, N. Miller, M. J. Kerin (2022) “Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer: A Prospective, Multicenter Clinical Trial.” Ann Surg 276(5):905-912. PMID: 35876391. |
| 10-11: Circulating miRNAs | Davey, M. G., A. McGuire, M. C. Casey, R. M. Waldron, M. Paganga, E. Holian, J. Newell, H. M. Heneghan, A. M. McDermott, M. M. Keane, A. J. Lowery, N. Miller, M. J. Kerin (2022) “Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial” J Am Coll Surg. 236(2):317-327. PMID: 36648259. |
| 14-11: Penelope-B | Galactionova, K., S. Loibl, P. Salari, F. Marmé, M. Martin, M. Untch, H. R. Bonnefoi, S. Kim, H. D. Bear, N. McCarthy, K. A. Gelmon, J. A. García-Sáenz, C. M. Kelly, T. Reimer, M. Toi, H.S Rugo, M. Gnant, A. Makris, N. Burchardi, M. Schwenkglenks (2022) “Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.” Front Oncol 12:886831. PMID: 36132153. |
| 12-43: PALOMA-2 | Rugo, H. S, S. Im, A. A. Joy, Y. Shparyk, J. M. Walshe, B. Sleckman, S. Loi, K. P. Theall, S. Kim, X. Huang, E. Bananis, R. Mahtani, R. S. Finn, V. Diéras (2022) “Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3” Breast 66:324-331. PMID: 36463643. |
| 15-49: NeoTRIP | Gianni, L., C. S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, G. Bianchini, S. Russo, E. M. Ciruelos, R. Greil, V. Semiglazov, M. Colleoni, C. Kelly, G. Mariani, L. Del Mastro, I. Maffeis, P. Valagussa, G. Viale (2022) “Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study” Ann Oncol 33(5):534-543. PMID: 351827219. |
| 14-19: BMS CA209-142/ CheckMate 142 | André, T., S. Lonardi, K Y M Wong, H-J Lenz, F. Gelsomino, M. Aglietta, M. A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, S. Abdullaev, A. Memaj, M. Lei, M. Dixon, S. Kopetz , M. J. Overman (2022) “Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.” Ann Oncol 33(10):1052-1060. PMID: 35764271. |
| 12-38: TRI-LARC | Geary, R., C. Gillham, G. McVey, J. Armstrong, M. Cunningham, G. Rangaswamy, D. Sharma, N. Wallace, C. Skourou, M. Dunne, M. Mahon, S. Bradshaw, L. Osullivan, J. Marron, I. Parker, A. Shannon, R. Mcdermott, S. Toomey, B. Hennessy, B. O’Neill (2022) “Quality of life analysis of a phase II randomised controlled trial comparing 3D-Conformal Radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy (IMRT) in locally advanced rectal cancer (TRI-LARC).” Int J of Rad Onc Vol 114 (3): S152. |
| 14-06: ENZAMET | Stockler, M. R., A. J. Martin, I. D. Davis, H. M. Dhillon, S. D. Begbie, K. N. Chi, S. Chowdhury, X. Coskinas, M. Frydenberg, W. E. Hague, L. G. Horvath, A. M. Joshua, N. J. Lawrence, G. M. Marx, J. McCaffrey, R. McDermott, M. McJannett, S. A. North, F. Parnis, W. R. Parulekar, D. W. Pook, M. N. Reaume, S. Sandhu, A. Tan, T. H. Tan, A. Thomson, F. Vera-Badillo, S. G. Williams, D. G. Winter, S. Yip, A. Y. Zhang, R. R. Zielinski, C. J. Sweeney & ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Group (ANZUP) (2022). “Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.” J Clin Oncol, 40(8): 837-846. PMID: 34928708. |
| 13-09: PEACE-1 | Fizazi, K., S. Foulon , J. Carles, G. Roubaud , R. McDermott , A. Fléchon , B. Tombal , S. Supiot , D. Berthold , P. Ronchin, G. Kacso, G. Gravis, F. Calabro, J.F Berdah, A. Hasbini, M. Silva, A.T Vuillemin, I. Latorzeff, L. Mourey, B. Laguerre, S.A Lacourtoisie, E. Martin, C. El. Kouri, A. Escande, A. Rosello, N. Magne, F. Schlurmann, F. Priou, M. C. Fouche, S.V Freixa, M. Jamaluddin, I. Rieger, A. Bossi, PEACE-1 investigators (2022). “Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.” Lancet 399(10336):1695-1707 PMID: 35405085. |
| (ICORG 97-01) Prostate | Kishan, A. U., Y. Sun, H. Hartman, T. M. Pisansky, M. Bolla, A. Neven, A. Steigler, J. W. Denham, F. Y. Feng, A. Zapatero, J. G. Armstrong, A. Nabid, N. Carrier, L. Souhami, M. T. Dunne, J. A. Efstathiou, H. M. Sandler, A. Guerrero, D. Joseph, P. Maingon, T. M. Reijke, X. Maldonado, T. Martin Ma, T. Romero, X. Wang, M. B Rettig, R. E Reiter, N. G Zaorsky, M. L Steinberg, N. G Nickols, A. Y Jia, J. A Garcia, D. E Spratt, MARCAP Consortium group (2022). “Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.” Lancet Oncol 23(2):304-316. PMID: 35051385. |
| 97-01 Prostate (a meta analysis) | Ma, T. M, F. Chu, H. Sandler, F. Y. Feng, J. A. Efstathiou, C. U. Jones, M. Roach, S. A. Rosenthal, T. Pisansky, J. M. Michalski, M. Bolla, T. M. Reijke, P. Maingon, A. Neven, J. Denham, A. Steigler, D. Joseph, A. Nabid, L. Souhami, N. Carrier, L. Incrocci, W. Heemsbergen, F. J. Pos, M. R. Sydes, D. P. Dearnaley, A. C. Tree, I. Syndikus, E. Hall, C. Cruickshank, S. Malone, S. Roy, Y. Sun, N. G. Zaorsky, N. G. Nickols, R. E. Reiter, M. B. Rettig, M. L. Steinberg, V. K. Reddy, M. Xiang, T. Romero, D. E. Spratt, A. U. Kishan (2022). “Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).” Eur Urol 82(5):487-498. PMID: 35934601. |
| 15-46: PACE-B | Tree C. A., P. Ostler, H. van der Voet, W. Chu, A. Loblaw, D. Ford, S. Tolan, S. Jain, A. Martin, J. Staffurth, J. Armstrong, P. Camilleri, K. Kancherla, J. Frew, A. Chan, I. S. Dayes, A. Duffton, D. H. Brand, D. Henderson, K. Morrison, S. Brown, J. Pugh, S. Burnett, M. Mahmud, V. Hinder, O. Naismith, E. Hall, As. N. Van, PACE Trial Investigators (2022) “Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.” Lancet Oncol 1308-1320. PMID: 36113498 |
| 07-11: SCC Retreat | Wallace, N. D., M. T. Dunne, O. McArdle, C. Small, I. Parker, A. M. Shannon, A. Clayton-Lea, M. Parker, C. D. Collins, J. G. Armstrong, C. Gillham, J. Coffey, D. Fitzpatrick, O. Salib, M. Moriarty, M. R. Stevenson, A. Alvarez-Iglesias, M. McCague, P. G. Thirion “Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trial” (2023) Br J Cancer 128(4):576-585. PMID: 36482188. |
| 17-30: IRONMAN | Mucci, L. A, J. Vinson, T. Gold, T. Gerke, J. Filipenko, R. M. Green, S. G. Anderson, S. Badal, A. Bjartell, K. N. Chi, I. D. Davis, D. Enting, A. P. Fay, J. Lazarus, J. Mateo, R. McDermott, F. T. Odedina, D. Olmos, A. Omlin, A. A. Popoola, C. Ragin, R. Roberts, K. M. Russnes, C. Waihenya, K. H. Stopsack, T. Hyslop, P. Villanti, P. W. Kantoff, D. J. George, IRONMAN Global Team (2022) “IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer” JCO Glob Oncol e2200154. PMID: 36332173. |
| 16-04: PRIMA | O’Cearbhaill, R. E., Jose-Alejandro Pérez-Fidalgo, B. J Monk, I. Tusquets, C. McCormick, J. Fuentes, R. G. Moore, C. Vulsteke, M. S. Shahin, F. Forget, W. H. Bradley, S. Hietanen, D. M. O’Malley, A. Dørum, B. M. Slomovitz, K. Baumann, F. Selle , P. M. Calvert, G. Artioli, T. Levy, A. Kumar, I. A. Malinowska, Y. Li, D. Gupta, Antonio G. M (2022) “Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.” Gynecol Oncol 166(1):36-43. PMID: 35550709. |
| 18-26: ATHENA | Monk, B. J., C. Parkinson, M. Cheol Lim, D. M. O’Malley, A. Oaknin, M. K. Wilson, R. L. Coleman, D. Lorusso, P. Bessette, S. Ghamande, A. Christopoulou, D. Provencher, E. Prendergast, F. Demirkiran, O. Mikheeva, O. Yeku, A. Chudecka-Glaz, M. Schenker, R. D. Littell, T. Safra, H. Chou, M.A. Morgan, V. Drochýtek, J. N. Barlin, T. Van Gorp, F. Ueland, G. Lindahl, C. Anderson, D. C. Collins, K. Moore, F. Marme, S. N. Westin, I. A. McNeish, D. Shih, K. K. Lin, S. Goble, S. Hume, K. Fujiwara, R. S. Kristeleit (2022) “A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).” J Clin Oncol JCO.22.01003. PMID: 35658487. |
| 11-21: ICON 8B | Clamp, A. R., E. C. James, I. A. McNeish, A. Dean, J. Kim, D. M. O’Donnell, D. Gallardo-Rincon, S. Blagden, J. Brenton, T. J. Perren, S. Sundar, R. Lord, G. Dark, M. Hall, S. Banerjee, R. M. Glasspool, C. Louise Hanna, S. Williams, K. M. Scatchard, H. Nam, S. Essapen, C. Parkinson, L. McAvan, A. Marie Swart, B. Popoola, F. Schiavone, J. Badrock, F. Fananapazir, A. D. Cook, M. Parmar, R. Kaplan, J. A. Ledermann (2022) “Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.” Lancet Oncol 23(7):919-930. PMID: 35690073. |
| Mac Eochagain, C., R. Power, I. Parker & D. Brennan (2022). “HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis.” J Gynecol Oncol, 33(3): e24. PMID: 35128855. | |
| Woopen, H., J. Sehouli, A. Davis, Y. C. Lee, P. A. Cohen, A. Ferrero, N. Gleeson, A. Jhingran, Y. Kajimoto, J. Mayadev, M. P. Barretina-Ginesta, S. Sundar, N. Suzuki, E. van Dorst & F. Joly (2022).” Erratum to “GCIG-Consensus guideline for long-term survivorship in gynecologic cancer: A position paper from the Gynecologic Cancer InterGroup (GCIG) symptom benefit committee” [Cancer Treatm. Rev. 107 (2022) 102396].” Cancer Treat Rev 109:102431. PMID: 35803179. | |
| 10-12: ANZGOG-0701 Symptom Benefit Study | Lee, Y. C., M. T. King, R. L. O’Connell, A. Lanceley, F. Joly, F. Hilpert, A. Davis, F. T. Roncolato, A. Okamoto, J. Bryce, P. Donnellan, A. M. Oza, E. Avall-Lundqvist, J. S. Berek, J. A. Ledermann, D. Berton, J. Sehouli, A. Feeney, M. Kaminsky, K. Diamante, M. R. Stockler, M. L. Friedlander, GCIG Symptom Benefit Group (2022) “Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecological Cancer Inter-Group-Symptom Benefit Study.” Int J Gynecol Cancer 32(6):761-768. PMID: 35086926. |
| Woopen, H., J. Sehouli, A. Davis, Y. C. Lee, P. A. Cohen, A. Ferrero, N. Gleeson, A. Jhingran, Y. Kajimoto, J. Mayadev, M. P. Barretina-Ginesta, S. Sundar, N. Suzuki, E. van Dorst, F. Joly (2022)“GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee” Cancer Treat Rev. 107:102396. PMID: 35525106. | |
| 16-59: ETOP ALERT | Felip, E., E. F. Smit, M. A. Molina-Vila, U. Dafni, B. Massuti, T. Berghmans, F.de Marinis, F. Passiglia, A. C. Dingemans, M. Cobo, S. Viteri, C. Britschgi, S. Cuffe, M. Provencio, S. Merkelbach-Bruse, C. Andriakopoulou, R. Kammler, B. Ruepp, H. Roschitzki-Voser, S. Peters, J. Wolf, R. Stahel, ETOP 12-17 ALERT-lung Collaborators (2022) “Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.” Lung Cancer 172:94-99. PMID: 36030612. |
| 16-61: ETOP BOOSTER | Dafni, U., R. A. Soo, S. Peters, Z. Tsourti, P. Zygoura, K. Vervita, J-Y Han, J. De Castro, L. Coate, M. Früh, S. M S. Hashemi, E. Nadal, E. Carcereny, M. A. Sala, R. Bernabé, M. Provencio, S. Cuffe, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R. A. Stahel (2022) “Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.“ ESMO Open 7(3):100507. PMID: 356967466. |
| 20-02: TERAVOLT Registry | LWhisenant, J. G., J. Baena, A. Cortellini, L. C. Huang, G. L. Russo, L. Porcu, S. K. Wong, C. M. Bestvina, M. D. Hellman, E. Roca, H. Rizvi, I. Monnet, A. Boudjemaa, J. Rogado, G. Pasello, N. B. Leighl, O. Arrieta, A. Aujayeb, U. Batra, A. Y. Azzam, M. Unk, M. A. Azab, A. N. Zhumagaliyeva, C. Gomez-Martin, J. B. Blaquier, E. Geraedts, G. Mountzios, G. Serrano-Montero, N. Reinmuth, L. Coate, M. Marmarelis, C. J. Presely, F. R. Hirsch, P. Garrido, H. Khan, A. Baggi, C. Mascaux, B. Halmos, G. L. Ceresoli, M. J. Fidler, V. Scotti, A. C. Métivier, L. Falchero, E. Felip, C. Genova. J. Mazieres, U. Tapan, J. Brahmer, E. Bria, S. Puri, S. Popat, K. L. Reckamp, F. Morgillo, E. Nadal, F. Mazzoni, F. Agustoni, J. Bar, F. Grosso, V. Avrillon, J. D. Patel, F. Gomes, E. Ibrahim, A. Trama, A. C. Bettini, F. Barlesi, A. M. Dingemans, H. Wakelee, S. Peters, L. Horn, M. C. Garassino, V. Torri & TERAVOLT study group (2022). “A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.” J Thorac Oncol, 17(5): 661-674. PMID: 35121086. |
| 13-17: RsqVD | O’Gorman, P., J. P. Laubach, M. E. O’Dwyer, J. Krawczyk, A. J. Yee, O. Gilligan, M. R. Cahill, J. Rosenblatt, J. Quinn, P. T. Murphy, H. DiPietro, M. R. Perera, G. M. Crotty, K. Cummings, P. J. Hayden, P. Browne, A. Savell, H. M. O’Leary, D. O’Keeffe, K. Masone, B. J. Hennessy, T. G. Garcia, K. Scott, K. Saeed, G. Bianchi, P. Dowling, C. Tierney & P. G. Richardson (2022). “Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.” Am J Hematol, 97(5): 562-573. PMID: 35132679. |
| 16-02: CyBorD-DARA | Swan, D., R. Henderson, C. McEllistrim, S. D. Naicker, J. Quinn, M. R. Cahill, V. Mykytiv, E. Lenihan, E. Mulvaney, M. Nolan, I. Parker, A. Natoni, K. Lynch, A. E. Ryan, E. Szegezdi, J. Krawczyk, P. Murphy, M. O’Dwyer (2022) “CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.” Clin Lymphoma Myeloma Leuk 22(11):847-852. PMID: 35985959. |
| O’Reilly, S., V. Murphy, E. Mulroe, L. Tucker, F. Carragher, J. Marron, A. Shannon, K. Rogan, R. M. Connolly, B. T. Hennessy, R. S. McDermott 1 (2022) “The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy” Cancers (Basel) 14(9):2247. PMID: 35565375. | |
Study Number: Short Name |
2021 Journal Publications |
| 06-31: TAILORx Study | Albain, K. S., R. J. Gray, D. F. Makower, A. Faghih, D. F. Hayes, C. E. Geyer, E. C. Dees, M. P. Goetz, J. A. Olson, T. Lively, S. S. Badve, T. J. Saphner, L. I. Wagner, T. J. Whelan, M. J. Ellis, W. C. Wood, M. M. Keane, H. L. Gomez, P. S. Reddy, T. F. Goggins, I. A. Mayer, A. M. Brufsky, D. L. Toppmeyer, V. G. Kaklamani, J. L. Berenberg, J. Abrams, G. W. Sledge and J. A. Sparano (2021). “Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.” J Natl Cancer Inst 113(4): 390-399. |
| 10-05: TCHL | Eustace, A. J., S. F. Madden, J. Fay, D. M. Collins, E. W. Kay, K. M. Sheehan, S. Furney, B. Moran, A. Fagan, P. G. Morris, A. Teiserskiene, A. D. Hill, L. Grogan, J. M. Walshe, O. Breathnach, C. Power, D. Duke, K. Egan, W. M. Gallagher, N. O’Donovan, J. Crown, S. Toomey and B. T. Hennessy (2021). “The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.” Breast Cancer Res Treat 187(3): 635-645. |
| 11-24: NSABP B47 | Ganz, P. A., R. S. Cecchini, L. Fehrenbacher, C. E. Geyer, P. Rastogi, J. P. Crown, M. P. Thirlwell, D. M. Ellison, J. F. Boileau, P. J. Flynn, J. H. Jeong, E. P. Mamounas and N. Wolmark (2021). “NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.” NPJ Breast Cancer 7(1): 55. |
| 11-03: SOLE | Guerini-Rocco, E., K. P. Gray, C. Fumagalli, M. R. Reforgiato, I. Leone, P. Rafaniello Raviele, E. Munzone, R. Kammler, P. Neven, E. Hitre, G. Jerusalem, E. Simoncini, A. Gombos, I. Deleu, P. Karlsson, S. Aebi, J. Chirgwin, V. Di Lauro, A. Thompson, M. P. Graas, M. Barber, C. Fontaine, S. Loibl, J. Gavilá, K. Kuroi, B. Müller, S. O’Reilly, A. Di Leo, A. Goldhirsch, G. Viale, M. Barberis, M. M. Regan and M. Colleoni (2021). “Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.” Clin Cancer Res 27(2): 504-512. |
| 15-02 PantHER | Keegan, N. M., S. J. Furney, J. M. Walshe, G. Gullo, M. J. Kennedy, D. Smith, J. McCaffrey, C. M. Kelly, K. Egan, J. Kerr, M. Given, P. O’Donovan, A. Hernando, A. Teiserskiene, I. Parker, E. Kay, A. Farrelly, A. Carr, G. Calzaferri, R. McDermott, M. M. Keane, L. Grogan, O. Breathnach, P. G. Morris, S. Toomey and B. T. Hennessy (2021). “Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”.” Cancers (Basel) 13(6). |
| 15-17: PALLAS | Blagden, S. P., A. D. Cook, C. Poole, L. Howells, I. A. McNeish, A. Dean, J. W. Kim, D. M. O’Donnell, J. Hook, E. C. James, I. R. White, T. Perren, R. Lord, G. Dark, H. M. Earl, M. Hall, R. Kaplan, J. A. Ledermann & A. R. Clamp (2020) “Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.” Lancet Oncol, 21, 969-977. |
| 11-29: ICON 8B | Mayer, E. L., A. C. Dueck, M. Martin, G. Rubovszky, H. J. Burstein, M. Bellet-Ezquerra, K. D. Miller, N. Zdenkowski, E. P. Winer, G. Pfeiler, M. Goetz, M. Ruiz-Borrego, D. Anderson, Z. Nowecki, S. Loibl, S. Moulder, A. Ring, F. Fitzal, T. Traina, A. Chan, H. S. Rugo, J. Lemieux, F. Henao, A. Lyss, S. Antolin Novoa, A. C. Wolff, M. Vetter, D. Egle, P. G. Morris, E. P. Mamounas, M. J. Gil-Gil, A. Prat, H. Fohler, O. Metzger Filho, M. Schwarz, C. DuFrane, D. Fumagalli, K. P. Theall, D. R. Lu, C. H. Bartlett, M. Koehler, C. Fesl, A. DeMichele and M. Gnant (2021) “Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.” Lancet Oncol 22(2): 212-222. |
| 18-27: PORTEC 4a | Wortman, B. G., E. Astreinidou, M. S. Laman, E. M. van der Steen-Banasik, L. C. H. W. Lutgens, H. Westerveld, F. Koppe, A. Slot, H. A. van den Berg, M. E. Nowee, S. Bijmolt, T. C. Stam, A. G. Zwanenburg, J. W. M. Mens, I. M. Jürgenliemk-Schulz, A. Snyers, C. M. Gillham, N. Weidner, S. Kommoss, K. Vandecasteele, V. Tomancova, C. L. Creutzberg, R. A. Nout and P. S. Group (2020). “Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer.” Radiother Oncol 155: 160-166. |
Study Number: Short Name |
2020 Journal Publication |
| 11-29: ICON 8B | Blagden, S. P., A. D. Cook, C. Poole, L. Howells, I. A. McNeish, A. Dean, J. W. Kim, D. M. O’Donnell, J. Hook, E. C. James, I. R. White, T. Perren, R. Lord, G. Dark, H. M. Earl, M. Hall, R. Kaplan, J. A. Ledermann & A. R. Clamp (2020) “Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.” Lancet Oncol, 21, 969-977. |
| 15-21: The ExPeCT Trial
|
Brady, L., B. Hayes, G. Sheill, A. M. Baird, E. Guinan, B. Stanfill, T. Vlajnic, O. Casey, V. Murphy, J. Greene, E. H. Allott, J. Hussey, F. Cahill, M. Van Hemelrijck, N. Peat, L. Mucci, M. Cunningham, L. Grogan, T. Lynch, R. P. Manecksha, J. McCaffrey, D. O’Donnell, O. Sheils, J. O’Leary, S. Rudman, R. McDermott & S. Finn (2020) “Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial.” PLoS One, 15, e0243928. |
| 08-17: IMRT Prostate | Cullen, D., J. Bryant, A. Maguire, D. Medipally, B. McClean, L. Shields, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, O. Howe, A. D. Meade & F. M. Lyng (2020) “Raman spectroscopy of lymphocytes for the identification of prostate cancer patients with late radiation toxicity following radiotherapy.” Translational Biophotonics, e201900035, 2627-1850. |
| 11-24: NSABP B47 | Fehrenbacher, L., R. S. Cecchini, C. E. Geyer, P. Rastogi, J. P. Costantino, J. N. Atkins, J. P. Crown, J. Polikoff, J. F. Boileau, L. Provencher, C. Stokoe, T. D. Moore, A. Robidoux, P. J. Flynn, V. F. Borges, K. S. Albain, S. M. Swain, S. Paik, E. P. Mamounas and N. Wolmark (2020). “NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.” J Clin Oncol 38(5): 444-453. |
| 15-42: LOXO 101 Study | Hong, D. S., S. G. DuBois, S. Kummar, A. F. Farago, C. M. Albert, K. S. Rohrberg, C. M. van Tilburg, R. Nagasubramanian, J. D. Berlin, N. Federman, L. Mascarenhas, B. Geoerger, A. Dowlati, A. S. Pappo, S. Bielack, F. Doz, R. McDermott, J. D. Patel, R. J. Schilder, M. Tahara, S. M. Pfister, O. Witt, M. Ladanyi, E. R. Rudzinski, S. Nanda, B. H. Childs, T. W. Laetsch, D. M. Hyman & A. Drilon (2020) “Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.” Lancet Oncol, 21, 531-540. |
| 15-43: CRQ Survey Study | Kearns, C., R. Feighery, J. Mc Caffrey, M. Higgins, M. Smith, V. Murphy, S. O’Reilly, A. M. Horgan, J. Walshe, R. McDermott, P. G. Morris, M. Keane, M. Martin, C. Murphy, K. Duffy, A. Mihai, J. Armstrong, D. M. O’Donnell, W. M. Gallagher & C. M. Kelly (2020) “Understanding and Attitudes toward Cancer Clinical Trials among Patients with a Cancer Diagnosis: National Study through Cancer Trials Ireland.” Cancers (Basel), 12. |
| 06-15/97-01: Proteomic Prostate study/Prostate | Keenan, L. G., N. Ibrahim, M. T. Dunne, M. Finn & J. G. Armstrong (2020) “The effect of anaemia on normal tissue toxicity and survival outcomes in prostate cancer treated with radical radiotherapy and neo-adjuvant androgen deprivation.” Br J Radiol, 93, 20190577. |
| 14-12: MDV3100-12 | Krop, I., V. Abramson, M. Colleoni, T. Traina, F. Holmes, L. Garcia-Estevez, L. Hart, A. Awada, C. Zamagni, P. G. Morris, L. Schwartzberg, S. Chan, A. Gucalp, L. Biganzoli, J. Steinberg, L. Sica, M. Trudeau, D. Markova, J. Tarazi, Z. Zhu, T. O’Brien, C. M. Kelly, E. Winer & D. A. Yardley (2020) “A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer.” Clin Cancer Res, 26, 6149-6157. |
| Lewison, G., A. Gavin, K. McCallion, R. McDermott, R. Sullivan & M. Lawler (2020) “The ‘Good Friday Agreement’ and cancer research on the island of Ireland: Evidence for the impact of a tripartite cancer research partnership.” Eur J Cancer, 129, 15-22. | |
| 10-11: Circulating miRNA’s | McGuire, A., M. C. Casey, R. M. Waldron, H. Heneghan, O. Kalinina, E. Holian, A. McDermott, A. J. Lowery, J. Newell, R. M. Dwyer, N. Miller, M. Keane, J. A. L. Brown & M. J. Kerin (2020) “Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.” Cancers (Basel), 12. |
| 08-17: IMRT Prostate | Medipally, D. K. R., D. Cullen, V. Untereiner, J. Bryant, G. D. Sockalingum, T. N. Q. Nguyen, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, A. D. Meade & F. M. Lyng (2020) “Effect of hemolysis on Fourier transform infrared and Raman spectra of blood plasma.” J Biophotonics, 13, e201960173. |
| 08-17: IMRT Prostate | Medipally, D. K. R., D. Cullen, V. Untereiner, G. D. Sockalingum, A. Maguire, T. N. Q. Nguyen, J. Bryant, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, A. D. Meade & F. M. Lyng (2020) “Vibrational spectroscopy of liquid biopsies for prostate cancer diagnosis.” Ther Adv Med Oncol, 12, 1758835920918499. |
| 12-24 ETOP BELIEF | Molina-Vila, M. A., R. A. Stahel, U. Dafni, N. Jordana-Ariza, A. Balada-Bel, M. Garzón-Ibáñez, B. García-Peláez, C. Mayo-de-Las-Casas, E. Felip, A. Curioni Fontecedro, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. Ponce Aix, E. Carcereny, M. Früh, M. Pless, S. Popat, S. Cuffe, P. Bidoli, R. Kammler, H. Roschitzki-Voser, Z. Tsourti, N. Karachaliou and R. Rosell (2020). “Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.“ J Thorac Oncol 15(3): 416-425. |
| 10-06: TROG DCIS | Olivotto, I. A., E. Link, C. Phillips, T. J. Whelan, G. Bryant, I. H. Kunkler, A. H. Westenberg, K. Purohit, V. Ahern, P. H. Graham, M. Akra, O. McArdle, J. J. Ludbrook, J. A. Harvey, J. H. Maduro, C. Kirkove, G. Gruber, J. D. Martin, I. D. Campbell, G. P. Delaney, B. H. Chua and B.-T. t. investigators (2020). “International comparison of cosmetic outcomes of breast conserving surgery and radiation therapy for women with ductal carcinoma in situ of the breast.” Radiother Oncol 142: 180-185. |
| 12-53: ETOP SPLENDOUR | Peters, S., S. Danson, B. Hasan, U. Dafni, N. Reinmuth, M. Majem, K. G. Tournoy, M. T. Mark, M. Pless, M. Cobo, D. Rodriguez-Abreu, L. Falchero, T. Moran, A. L. Ortega Granados, I. Monnet, K. Mohorcic, B. M. Sureda, D. Betticher, I. Demedts, J. A. Macias, S. Cuffe, A. Luciani, J. G. Sanchez, A. Curioni-Fontecedro, O. Gautschi, G. Price, L. Coate, R. von Moos, C. Zielinski, M. Provencio, J. Menis, B. Ruepp, A. Pochesci, H. Roschitzki-Voser, B. Besse, M. Rabaglio, M. E. R. O’Brien & R. A. Stahel (2020) “A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.” J Thorac Oncol, 15, 1647-1656. |
| 10-12: ANZGOG-0701 symptom benefit study | Roncolato, F. T., R. L. O’Connell, F. Joly, A. Lanceley, F. Hilpert, L. Buizen, A. Okamoto, E. Aotani, V. Salutari, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. Berek, T. Fehm, J. Ledermann, C. Roemer-Becuwe, M. R. Stockler, M. T. King and M. L. Friedlander (2020). “Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS).” Gynecol Oncol 156(1): 45-53. |
| 12-43: TRIO 022/ PALOMA-2
|
Rugo, H. S., R. S. Finn, K. Gelmon, A. A. Joy, N. Harbeck, A. Castrellon, H. Mukai, J. M. Walshe, A. Mori, E. Gauthier, D. R. Lu, E. Bananis, M. Martin & V. Diéras (2020) “Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.” Clin Breast Cancer, 20, e173-e180. |
| 06-31: TAILORx Study
|
Sparano, J. A., R. J. Gray, D. F. Makower, K. S. Albain, T. J. Saphner, S. S. Badve, L. I. Wagner, V. G. Kaklamani, M. M. Keane, H. L. Gomez, P. S. Reddy, T. F. Goggins, I. A. Mayer, D. L. Toppmeyer, A. M. Brufsky, M. P. Goetz, J. L. Berenberg, C. Mahalcioiu, C. Desbiens, D. F. Hayes, E. C. Dees, C. E. Geyer, J. A. Olson, W. C. Wood, T. Lively, S. Paik, M. J. Ellis, J. Abrams & G. W. Sledge (2020) “Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.” JAMA Oncol, 6, 367-374. |
| 16-20: IBCSG 48-14 POSITIVE | Sun, Z., S. M. Niman, O. Pagani, A. H. Partridge, H. A. Azim, F. A. Peccatori, M. Ruggeri, A. Di Leo, M. Colleoni, R. D. Gelber, M. M. Regan & P. S. Committee (2020) “Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial”. Breast, 53, 1-7.
*Cancer Trials Ireland author (member of the Positive Steering committee) listed in the appendix |
| 05-03: Spinal Cord Compression | Thirion, P. G., M. T. Dunne, P. J. Kelly, A. Flavin, J. M. O’Sullivan, D. Hacking, W. Sasiadek, C. Small, M. M. Pomeroy, J. Martin, O. McArdle, I. Parker, L. S. O’Sullivan, A. M. Shannon, A. Clayton-Lea, C. D. Collins, M. R. Stevenson, A. Alvarez-Iglesias, J. G. Armstrong & M. Moriarty (2020) “Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression.” Br J Cancer, 122, 1315-1323. |
| 12-09: CharactHer | Walsh, N., C. Andrieu, P. O’Donovan, C. Quinn, A. Maguire, S. J. Furney, G. Gullo & J. Crown (2020) “Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer.” Br J Cancer, 123, 1219-1222. |
Study Number: Short Name |
2019 Journal Publications |
| 11-29: ICON 8B | Clamp, A. R., E. C. James, I. A. McNeish, A. Dean, J. W. Kim, D. M. O’Donnell, J. Hook, C. Coyle, S. Blagden, J. D. Brenton, R. Naik, T. Perren, S. Sundar, A. D. Cook, G. S. Gopalakrishnan, H. Gabra, R. Lord, G. Dark, H. M. Earl, M. Hall, S. Banerjee, R. M. Glasspool, R. Jones, S. Williams, A. M. Swart, S. Stenning, M. Parmar, R. Kaplan and J. A. Ledermann (2019). “Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.” Lancet 394(10214): 2084-2095. |
| 14-06: ANZUP ENZAMET Study | Davis, I. D., A. J. Martin, M. R. Stockler, S. Begbie, K. N. Chi, S. Chowdhury, X. Coskinas, M. Frydenberg, W. E. Hague, L. G. Horvath, A. M. Joshua, N. J. Lawrence, G. Marx, J. McCaffrey, R. McDermott, M. McJannett, S. A. North, F. Parnis, W. Parulekar, D. W. Pook, M. N. Reaume, S. K. Sandhu, A. Tan, T. H. Tan, A. Thomson, E. Tu, F. Vera-Badillo, S. G. Williams, S. Yip, A. Y. Zhang, R. R. Zielinski, C. J. Sweeney and E. T. I. a. t. A. a. N. Z. U. a. P. C. T. Group (2019). “Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.” N Engl J Med 381(2): 121-131. |
| 08-10: TC-Avastin | Gullo, G., A. J Eustace, A. Canonici, D. M Collins, M. J. Kennedy, L. Grogan, O. Breathhnach, J. McCaffrey, M. Keane, M. J. Martin, R. Gupta, G. Leonard, M. O’Connor, P. M. Calvert, P. Donnellan, J. Walshe, E. McDermott, K. Scott, A. Hernando, I. Parker, D. W Murray, A. C O’Farrell, A. Maratha, P. Dicker, M. Rafferty, V. Murphy, N. O’Donovan, W. M Gallagher, B. Ky, D. Tryfonopoulos, B. Moulton, A. T Byrne and J. Crown (2019). “Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.” Ther Adv Med Oncol 11: 1758835919864236. |
| 06-35: PET-CT Lung | Lee, K. A., G. Rangaswamy, N. A. Lavan, M. Dunne, C. D. Collins, C. Small and P. Thirion (2019). “ICORG 06-35: a prospective evaluation of PET-CT scan in patients with non-operable or non-resectable non-small cell lung cancer treated by radical 3-dimensional conformal radiation therapy: a phase II study.” Ir J Med Sci 188(4): 1155-1161. |
| 06-32: NSABP 42
|
Mamounas, E. P., H. Bandos, B. C. Lembersky, J. H. Jeong, C. E. Geyer, P. Rastogi, L. Fehrenbacher, M. L. Graham, S. K. Chia, A. M. Brufsky, J. M. Walshe, G. S. Soori, S. R. Dakhil, T. E. Seay, J. L. Wade, E. C. McCarron, S. Paik, S. M. Swain, D. L. Wickerham and N. Wolmark (2019). “Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.” Lancet Oncol 20(1): 88-99. |
| 08-17: IMRT Prostate | Medipally, D. K. R., T. N. Q. Nguyen, J. Bryant, V. Untereiner, G. D. Sockalingum, D. Cullen, E. Noone, S. Bradshaw, M. Finn, M. Dunne, A. M. Shannon, J. Armstrong, F. M. Lyng and A. D. Meade (2019). “Monitoring Radiotherapeutic Response in Prostate Cancer Patients Using High Throughput FTIR Spectroscopy of Liquid Biopsies.” Cancers (Basel) 11(7). |
| 12-39: De-ESCALaTE HPV | Mehanna, H., M. Robinson, A. Hartley, A. Kong, B. Foran, T. Fulton-Lieuw, M. Dalby, P. Mistry, M. Sen, L. O’Toole, H. Al Booz, K. Dyker, R. Moleron, S. Whitaker, S. Brennan, A. Cook, M. Griffin, E. Aynsley, M. Rolles, E. De Winton, A. Chan, D. Srinivasan, I. Nixon, J. Grumett, C. R. Leemans, J. Buter, J. Henderson, K. Harrington, C. McConkey, A. Gray, J. Dunn and D.-E. H. T. Group (2019). “Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.” Lancet 393(10166): 51-60. |
| 16-02: CyBorD-DARA | O’Dwyer, M., R. Henderson, S. D. Naicker, M. R. Cahill, P. Murphy, V. Mykytiv, J. Quinn, C. McEllistrim, J. Krawczyk, J. Walsh, E. Lenihan, T. Kenny, A. Hernando, G. Hirakata, I. Parker, E. Kinsella, G. Gannon, A. Natoni, K. Lynch and A. E. Ryan (2019). “CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.” Blood Adv 3(12): 1815-1825. |
| 01-04: BCIRG 005 | Press, M. F., J. A. Seoane, C. Curtis, E. Quinaux, R. Guzman, G. Sauter, W. Eiermann, J. R. Mackey, N. Robert, T. Pienkowski, J. Crown, M. Martin, V. Valero, V. Bee, Y. Ma, I. Villalobos and D. J. Slamon (2019). “Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines.” JAMA Oncol 5(3): 366-375. |
| 14-13: MK3475-024 / KEYNOTE-024 | Reck, M., D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, K. Vandormael, A. Riccio, J. Yang, M. C. Pietanza and J. R. Brahmer (2019). “Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.“ J Clin Oncol 37(7): 537-546. |
| 15-10: OPTIMISMM | Richardson, P. G., A. Oriol, M. Beksac, A. M. Liberati, M. Galli, F. Schjesvold, J. Lindsay, K. Weisel, D. White, T. Facon, J. San Miguel, K. Sunami, P. O’Gorman, P. Sonneveld, P. Robak, S. Semochkin, S. Schey, X. Yu, T. Doerr, A. Bensmaine, T. Biyukov, T. Peluso, M. Zaki, K. Anderson, M. Dimopoulos and O. t. investigators (2019). “Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.” Lancet Oncol 20(6): 781-794. |
| 15-05: UPCI 10-028 / Oligo recurrent Stereotactic | Sutera, P., D. A. Clump, R. Kalash, D. D’Ambrosio, A. Mihai, H. Wang, D. P. Petro, S. A. Burton and D. E. Heron (2019). “Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.” Int J Radiat Oncol Biol Phys 103(1): 116-122. |
| 09-03: AGO-OVAR 16 (GSK: VEG110655) | Vergote, I., A. du Bois, A. Floquet, J. Rau, J. W. Kim, J. M. Del Campo, M. Friedlander, S. Pignata, K. Fujiwara, N. Colombo, M. R. Mirza, B. J. Monk, I. Tsibulak, P. M. Calvert, T. J. Herzog, L. C. Hanker, J. Meunier, J. Y. Lee, A. Bologna, M. J. Carrasco-Alfonso and P. Harter (2019). “Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.” Gynecol Oncol 155(2): 186-191. |
Study Number: Short Name |
2018 Journal Publications |
| 07-01: CLL-IRL | Appleby, N., D. O’Brien, F. M. Quinn, L. Smyth, J. Kelly, I. Parker, K. Scott, M. R. Cahill, G. Crotty, H. Enright, B. Hennessy, A. Hodgson, M. Leahy, H. O’Leary, M. O’Dwyer, A. Hayat and E. A. Vandenberghe (2018). “Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.” Leuk Lymphoma 59(6): 1338-1347. |
| 04-01: AZURE | Brown, J., E. Rathbone, S. Hinsley, W. Gregory, F. Gossiel, H. Marshall, R. Burkinshaw, H. Shulver, H. Thandar, G. Bertelli, K. Maccon, A. Bowman, A. Hanby, R. Bell, D. Cameron and R. Coleman (2018). “Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.” J Natl Cancer Inst 110(8): 871-879. |
| 99-09: 3DCRT Lung | Cagney, D. N., P. G. Thirion, M. T. Dunne, C. Fleming, D. Fitzpatrick, C. M. O’Shea, M. A. Finn, S. O’Sullivan, C. Booth, C. D. Collins, S. J. Buckney, A. Shannon and J. G. Armstrong (2018). “A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.” Clin Oncol (R Coll Radiol) 30(1): 30-38. |
| 12-40: EORTC 10085 | Cardoso, F., J. M. S. Bartlett, L. Slaets, C. H. M. van Deurzen, E. van Leeuwen-Stok, P. Porter, B. Linderholm, I. Hedenfalk, C. Schröder, J. Martens, J. Bayani, C. van Asperen, M. Murray, C. Hudis, L. Middleton, J. Vermeij, K. Punie, J. Fraser, M. Nowaczyk, I. T. Rubio, S. Aebi, C. Kelly, K. J. Ruddy, E. Winer, C. Nilsson, L. Dal Lago, L. Korde, K. Benstead, O. Bogler, T. Goulioti, A. Peric, S. Litière, K. C. Aalders, C. Poncet, K. Tryfonidis and S. H. Giordano (2018). “Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.” Ann Oncol 29(2): 405-417. |
| 11-03: SOLE | Colleoni, M., W. Luo, P. Karlsson, J. Chirgwin, S. Aebi, G. Jerusalem, P. Neven, E. Hitre, M. P. Graas, E. Simoncini, C. Kamby, A. Thompson, S. Loibl, J. Gavilá, K. Kuroi, C. Marth, B. Müller, S. O’Reilly, V. Di Lauro, A. Gombos, T. Ruhstaller, H. Burstein, K. Ribi, J. Bernhard, G. Viale, R. Maibach, M. Rabaglio-Poretti, R. D. Gelber, A. S. Coates, A. Di Leo, M. M. Regan, A. Goldhirsch and S. Investigators (2018). “Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.” Lancet Oncol 19(1): 127-138. |
| 06-02: SOFT | Francis, P. A., O. Pagani, G. F. Fleming, B. A. Walley, M. Colleoni, I. Láng, H. L. Gómez, C. Tondini, E. Ciruelos, H. J. Burstein, H. R. Bonnefoi, M. Bellet, S. Martino, C. E. Geyer, M. P. Goetz, V. Stearns, G. Pinotti, F. Puglisi, S. Spazzapan, M. A. Climent, L. Pavesi, T. Ruhstaller, N. E. Davidson, R. Coleman, M. Debled, S. Buchholz, J. N. Ingle, E. P. Winer, R. Maibach, M. Rabaglio-Poretti, B. Ruepp, A. Di Leo, A. S. Coates, R. D. Gelber, A. Goldhirsch, M. M. Regan and S. a. T. I. a. t. I. B. C. S. Group (2018). “Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.” N Engl J Med 379(2): 122-137.
* Cancer Trials Ireland authors listed in supplementary materials |
| 09-03: AGO-OVA 16 (GSK: VEG110655) | Friedlander, M., J. Rau, C. K. Lee, W. Meier, A. Lesoin, J. W. Kim, A. Poveda, M. Buck, G. Scambia, M. Shimada, F. Hilpert, M. T. King, P. Debruyne, A. Bologna, S. Malander, B. J. Monk, E. Petru, P. Calvert, T. J. Herzog, C. Barrett and A. du Bois (2018). “Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.” Ann Oncol 29(3): 737-743. |
| 12-45: SNAP | Gennari, A., Z. Sun, U. Hasler-Strub, M. Colleoni, M. J. Kennedy, R. Von Moos, J. Cortés, M. J. Vidal, B. Hennessy, J. Walshe, K. A. Parraga, K. Ribi, J. Bernhard, S. M. Murillo, O. Pagani, A. Barbeaux, S. Borstnar, M. Rabaglio-Poretti, R. Maibach, M. M. Regan, G. Jerusalem and C. n. T. I. a. S. G. International Breast Cancer Study Group (2018). “A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.” Ann Oncol 29(3): 661-668. |
| 10-12: ANZGOG-0701 symptom benefit study | King, M. T., M. R. Stockler, R. L. O’Connell, L. Buizen, F. Joly, A. Lanceley, F. Hilpert, A. Okamoto, E. Aotani, J. Bryce, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. S. Berek, J. Sehouli, A. Feeney, D. Berton-Rigaud, D. S. J. Costa, M. L. Friedlander and G. S. B. group (2018). “Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.” Qual Life Res 27(1): 59-74. |
| 15-20: P3BEP | Lawrence, N. J., H. Chan, G. Toner, M. R. Stockler, A. Martin, S. Yip, N. Wong, A. Yeung, D. Mazhar, F. Pashankar, L. Frazier, R. McDermott, R. Walker, H. Tan, I. D. Davis, P. Grimison and ANZUP (2018). “Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours.” BMC Cancer 18(1): 854. |
| 05-03: Spinal Cord Compression | Lee, K. A., M. Dunne, C. Small, P. J. Kelly, O. McArdle, J. O’Sullivan, D. Hacking, M. Pomeroy, J. Armstrong, M. Moriarty, A. Clayton-Lea, I. Parker, C. D. Collins and P. Thirion (2018). “(ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis.” Acta Oncol 57(7): 965-972. |
| 08-17: IMRT Prostate | Meade, A. D., A. Maguire, J. Bryant, D. Cullen, D. Medipally, L. White, B. McClean, L. Shields, J. Armstrong, M. Dunne, E. Noone, S. Bradshaw, M. Finn, A. M. Shannon, O. Howe and F. M. Lyng (2018). “Prediction of DNA damage and G2 chromosomal radio-sensitivity ex vivo in peripheral blood mononuclear cells with label-free Raman micro-spectroscopy.” Int J Radiat Biol: 1-10. |
| 06-34: Palliative Lung | McDermott, R. L., J. G. Armstrong, P. Thirion, M. Dunne, M. Finn, C. Small, M. Byrne, C. O’Shea, L. O’Sullivan, A. Shannon, E. Kelly and D. J. Hacking (2018). “Cancer Trials Ireland (ICORG) 06-34: A multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer.” Radiother Oncol 127(2): 253-258. |
| 05-04: Bladder-Filling Prostate Study | Mullaney, L., E. O’Shea, M. T. Dunne, P. G. Thirion and J. G. Armstrong (2018). “A comparison of bladder volumes based on treatment planning CT and BladderScan® BVI 6100 ultrasound device in a prostate radiation therapy population.” Br J Radiol 91(1091): 20180160. |
| 15-35: INTERVAL-GAP4 | Newton, R. U., S. A. Kenfield, N. H. Hart, J. M. Chan, K. S. Courneya, J. Catto, S. P. Finn, R. Greenwood, D. C. Hughes, L. Mucci, S. R. Plymate, S. F. E. Praet, E. M. Guinan, E. L. Van Blarigan, O. Casey, M. Buzza, S. Gledhill, L. Zhang, D. A. Galvão, C. J. Ryan and F. Saad (2018). “Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.” BMJ Open 8(5): e022899. |
| 14-19: BMS CA209-142/CheckMate 142 | Overman, M. J., S. Lonardi, K. Y. M. Wong, H. J. Lenz, F. Gelsomino, M. Aglietta, M. A. Morse, E. Van Cutsem, R. McDermott, A. Hill, M. B. Sawyer, A. Hendlisz, B. Neyns, M. Svrcek, R. A. Moss, J. M. Ledeine, Z. A. Cao, S. Kamble, S. Kopetz and T. André (2018). “Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.” J Clin Oncol 36(8): 773-779. |
| 10-12: ANZGOG-0701 symptom benefit study | Roncolato, F. T., D. Berton-Rigaud, R. O’Connell, A. Lanceley, J. Sehouli, L. Buizen, A. Okamoto, E. Aotani, D. Lorusso, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. Berek, F. Hilpert, J. A. Ledermann, M. C. Kaminsky, M. R. Stockler, M. T. King and M. Friedlander (2018). “Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).” Gynecol Oncol 148(1): 36-41. |
| 12-07: LCCC 1029 (Regorafenib) | Sanoff, H. K., R. M. Goldberg, A. Ivanova, S. O’Reilly, S. S. Kasbari, R. D. Kim, R. McDermott, D. T. Moore, W. Zamboni, W. Grogan, A. L. Cohn, T. S. Bekaii-Saab, G. Leonard, T. Ryan, O. O. Olowokure, N. H. Fernando, J. McCaffrey, B. F. El-Rayes, A. M. Horgan, G. B. Sherrill, G. H. Yacoub and B. H. O’Neil (2018). “Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.” Cancer 124(15): 3118-3126. |
| 12-16: AC-ANGIOPREDICT | Smeets, D., I. S. Miller, D. P. O’Connor, S. Das, B. Moran, B. Boeckx, T. Gaiser, J. Betge, A. Barat, R. Klinger, N. C. T. van Grieken, C. Cremolini, H. Prenen, M. Mazzone, J. Depreeuw, O. Bacon, B. Fender, J. Brady, B. T. Hennessy, D. A. McNamara, E. Kay, H. M. Verheul, N. Maarten, W. M. Gallagher, V. Murphy, J. H. M. Prehn, M. Koopman, C. J. A. Punt, F. Loupakis, M. P. A. Ebert, B. Ylstra, D. Lambrechts and A. T. Byrne (2018). “Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.” Nat Commun 9(1): 4112. |
| 98-01: BIG 2-98 | Sonnenblick, A., R. Salgado, S. Brohée, T. Zahavi, T. Peretz, G. Van den Eynden, G. Rouas, A. Salmon, P. A. Francis, A. Di Leo, J. P. A. Crown, G. Viale, L. Daly, B. Javdan, S. Fujisawa, E. De Azambuja, A. Lieveke, M. J. Piccart, J. F. Bromberg and C. Sotiriou (2018). “p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.” Int J Oncol 52(2): 424-432. |
| 06-31: TAILORx | Sparano, J. A., R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain, D. F. Hayes, C. E. Geyer, E. C. Dees, M. P. Goetz, J. A. Olson, T. Lively, S. S. Badve, T. J. Saphner, L. I. Wagner, T. J. Whelan, M. J. Ellis, S. Paik, W. C. Wood, P. M. Ravdin, M. M. Keane, H. L. Gomez Moreno, P. S. Reddy, T. F. Goggins, I. A. Mayer, A. M. Brufsky, D. L. Toppmeyer, V. G. Kaklamani, J. L. Berenberg, J. Abrams and G. W. Sledge (2018). “Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.” N Engl J Med 379(2): 111-121. |
| 12-16: AC-ANGIOPREDICT | van Dijk, E., H. D. Biesma, M. Cordes, D. Smeets, M. Neerincx, S. Das, P. P. Eijk, V. Murphy, A. Barat, O. Bacon, J. H. M. Prehn, J. Betge, T. Gaiser, B. Fender, G. A. Meijer, D. A. McNamara, R. Klinger, M. Koopman, M. P. A. Ebert, E. W. Kay, B. T. Hennessey, H. M. W. Verheul, W. M. Gallagher, D. P. O’Connor, C. J. A. Punt, F. Loupakis, D. Lambrechts, A. T. Byrne, N. C. T. van Grieken and B. Ylstra (2018). “Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.” J Clin Oncol 36(20): 2052-2060. |
Study Number: Short Name |
2017 Journal Publications |
| 14-13: MSD MK-3475-024 / KEYNOTE-024 | Brahmer, J. R., D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, J. Zhang, G. M. Lubiniecki, A. C. Deitz, R. Rangwala and M. Reck (2017). “Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.” Lancet Oncol 18(12): 1600-1609. |
| 97-01: Prostate, 02-01: Iressa Prostate, 05-04: Bladder-Filling Prostate study, 06-15: Proteomic Prostate study, 06-16: 3-D CRT vs. IMRT study, 08-17: IMRT Prostate | Cagney, D. N., M. Dunne, C. O’Shea, M. Finn, E. Noone, M. Sheehan, L. McDonagh, L. O’Sullivan, P. Thirion and J. Armstrong (2017). “Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.” BMC Urol 17(1): 60. |
| 04-02: TANGO | Earl, H. M., L. Hiller, H. C. Howard, J. A. Dunn, J. Young, S. J. Bowden, M. McDermaid, A. K. Waterhouse, G. Wilson, R. Agrawal, S. O’Reilly, A. Bowman, D. M. Ritchie, A. Goodman, T. Hickish, K. McAdam, D. Cameron, D. Dodwell, D. W. Rea, C. Caldas, E. Provenzano, J. E. Abraham, P. Canney, J. P. Crown, M. J. Kennedy, R. Coleman, R. C. Leonard, J. A. Carmichael, A. M. Wardley, C. J. Poole and t. t. collaborators (2017). “Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.” Lancet Oncol 18(6): 755-769. |
| Karam, A., J. A. Ledermann, J. W. Kim, J. Sehouli, K. Lu, C. Gourley, N. Katsumata, R. A. Burger, B. H. Nam, M. Bacon, C. Ng, J. Pfisterer, R. L. M. Bekkers, A. Casado Herráez, A. Redondo, H. Fujiwara, N. Gleeson, O. Rosengarten, G. Scambia, J. Zhu, A. Okamoto, G. Stuart, K. Ochiai and p. o. t. t. O. C. C. Conference (2017). “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.” Ann Oncol 28(4): 711-717. | |
| 08-17: IMRT Prostate | Medipally, D. K., A. Maguire, J. Bryant, J. Armstrong, M. Dunne, M. Finn, F. M. Lyng and A. D. Meade (2017). “Development of a high throughput (HT) Raman spectroscopy method for rapid screening of liquid blood plasma from prostate cancer patients.” Analyst 142(8): 1216-1226. |
| 12-16: AC-ANGIOPREDICT | Moran, B., S. Das, D. Smeets, G. Peutman, R. Klinger, B. Fender, K. Connor, M. Ebert, T. Gaiser, J. H. Prehn, O. Bacon, E. Kay, B. Hennessy, V. Murphy, B. Ylstra, D. Lambrechts, A. T. Byrne, W. M. Gallagher and D. P. O’Connor (2017). “Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.” Oncotarget 8(29): 48126-48137. |
| 11-05: GSK VEG113387 adjuvant pazopanib RCC study | Motzer, R. J., N. B. Haas, F. Donskov, M. Gross-Goupil, S. Varlamov, E. Kopyltsov, J. L. Lee, B. Melichar, B. I. Rini, T. K. Choueiri, M. Zemanova, L. A. Wood, M. N. Reaume, A. Stenzl, S. Chowdhury, H. Y. Lim, R. McDermott, A. Michael, W. Bao, M. J. Carrasco-Alfonso, P. Aimone, M. Voi, C. Doehn, P. Russo, C. N. Sternberg and P. investigators (2017). “Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.” J Clin Oncol 35(35): 3916-3923. |
| 14-19: BMS CA209-142/CheckMate 142 | Overman, M. J., R. McDermott, J. L. Leach, S. Lonardi, H. J. Lenz, M. A. Morse, J. Desai, A. Hill, M. Axelson, R. A. Moss, M. V. Goldberg, Z. A. Cao, J. M. Ledeine, G. A. Maglinte, S. Kopetz and T. André (2017). “Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.” Lancet Oncol 18(9): 1182-1191. |
| 12-25: ETOP EMPHASIS | Peters, S., R. A. Stahel, U. Dafni, S. Ponce Aix, B. Massuti, O. Gautschi, L. Coate, A. Lopez Martin, R. van Heemst, T. Berghmans, P. Meldgaard, M. Cobo Dols, J. Garde Noguera, A. Curioni-Fontecedro, D. Rauch, M. T. Mark, S. Cuffe, B. Biesma, A. M. van Henten, O. Juan Vidal, R. Palmero Sanchez, J. C. Villa Guzman, R. Collado Martin, S. Peralta, A. Insa, Y. Summers, I. Lang, A. Horgan, F. Ciardiello, S. de Hosson, R. Pieterman, H. J. Groen, P. M. van den Berg, C. C. Zielinski, Y. Chittazhathu Kurian Kuruvilla, A. Gasca-Ruchti, M. Kassapian, S. Novello, V. Torri, Z. Tsourti, V. Gregorc, E. F. Smit and E. M.-l. C. Group (2017). “Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.” J Thorac Oncol 12(4): 752-762. |
| 09-11: PAVES | Pinter, T., Z. Klippel, A. Cesas, A. Croitoru, J. Decaestecker, P. Gibbs, Y. Hotko, J. Jassem, G. Kurteva, J. Novotny, S. O’Reilly, T. Salek, M. Reiner, P. K. Morrow, M. R. Choi, S. Whittaker and C. Blanke (2016). “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).” Clin Colorectal Cancer 16(2): 103-114.e103. |
| 10-14: Neo-AEGIS | Reynolds, J. V., S. R. Preston, B. O’Neill, L. Baeksgaard, S. M. Griffin, C. Mariette, S. Cuffe, M. Cunningham, T. Crosby, I. Parker, K. Hofland, G. Hanna, L. B. Svendsen, C. L. Donohoe, C. Muldoon, D. O’Toole, C. Johnson, N. Ravi, G. Jones, A. K. Corkhill, M. Illsley, J. Mellor, K. Lee, M. Dib, V. Marchesin, M. Cunnane, K. Scott, P. Lawner, S. Warren, S. O’Reilly, G. O’Dowd, G. Leonard, B. Hennessy and R. M. Dermott (2017). “ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).” BMC Cancer 17(1): 401. |
| 10-12: ANZGOG-0701 symptom benefit study | Roncolato, F. T., F. Joly, R. O’Connell, A. Lanceley, F. Hilpert, L. Buizen, A. Okamoto, E. Aotani, S. Pignata, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. S. Berek, F. Heitz, A. Feeney, D. Berton-Rigaud, M. R. Stockler, M. King, M. Friedlander and G. S. B. group (2017). “Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.” Oncologist 22(9): 1117-1124. |
| 12-24: ETOP BELIEF | Rosell, R., U. Dafni, E. Felip, A. Curioni-Fontecedro, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. P. Aix, E. Carcereny, M. Früh, M. Pless, S. Popat, A. Kotsakis, S. Cuffe, P. Bidoli, A. Favaretto, P. Froesch, N. Reguart, J. Puente, L. Coate, F. Barlesi, D. Rauch, M. Thomas, C. Camps, J. Gómez-Codina, M. Majem, R. Porta, R. Shah, E. Hanrahan, R. Kammler, B. Ruepp, M. Rabaglio, M. Kassapian, N. Karachaliou, R. Tam, D. S. Shames, M. A. Molina-Vila, R. A. Stahel and B. c. group (2017). “Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.” Lancet Respir Med 5(5): 435-444. |
| 15-21: The ExPeCT Trial | Sheill, G., L. Brady, E. Guinan, B. Hayes, O. Casey, J. Greene, T. Vlajnic, F. Cahill, M. Van Hemelrijck, N. Peat, S. Rudman, J. Hussey, M. Cunningham, L. Grogan, T. Lynch, R. P. Manecksha, J. McCaffrey, L. Mucci, O. Sheils, J. O’Leary, D. M. O’Donnell, R. McDermott and S. Finn (2017). “The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.” Trials 18(1): 456. |
| 07-02: ALTTO | Sonnenblick, A., D. Agbor-Tarh, I. Bradbury, S. Di Cosimo, H. A. Azim, D. Fumagalli, S. Sarp, A. C. Wolff, M. Andersson, J. Kroep, T. Cufer, S. D. Simon, P. Salman, M. Toi, L. Harris, J. Gralow, M. Keane, A. Moreno-Aspitia, M. Piccart-Gebhart and E. de Azambuja (2017). “Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.” J Clin Oncol 35(13): 1421-1429. |
| 13-02: BMS CA209-067 / CheckMate 067 | Sznol, M., P. F. Ferrucci, D. Hogg, M. B. Atkins, P. Wolter, M. Guidoboni, C. Lebbé, J. M. Kirkwood, J. Schachter, G. A. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, D. Walker, R. Bhore, J. Jiang, F. S. Hodi and J. D. Wolchok (2017). “Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.” J Clin Oncol: JCO2016721167. |
| 10-05: TCHL | Toomey, S., A. J. Eustace, J. Fay, K. M. Sheehan, A. Carr, M. Milewska, S. F. Madden, A. Teiserskiene, E. W. Kay, N. O’Donovan, W. Gallagher, L. Grogan, O. Breathnach, J. Walshe, C. Kelly, B. Moulton, M. J. Kennedy, G. Gullo, A. D. Hill, C. Power, D. Duke, N. Hambly, J. Crown and B. T. Hennessy (2017). “Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.” Breast Cancer Res 19(1): 87. |
| 06-36: ECOG E1505 | Wakelee, H. A., S. E. Dahlberg, S. M. Keller, W. J. Tester, D. R. Gandara, S. L. Graziano, A. A. Adjei, N. B. Leighl, S. C. Aisner, J. M. Rothman, J. D. Patel, M. D. Sborov, S. R. McDermott, R. Perez-Soler, A. M. Traynor, C. Butts, T. Evans, A. Shafqat, A. E. Chapman, S. S. Kasbari, L. Horn, S. S. Ramalingam, J. H. Schiller and ECOG-ACRIN (2017). “Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.” Lancet Oncol 18(12): 1610-1623. |
| 97-01: Prostate | Xie, W., M. M. Regan, M. Buyse, S. Halabi, P. W. Kantoff, O. Sartor, H. Soule, N. W. Clarke, L. Collette, J. J. Dignam, K. Fizazi, W. R. Paruleker, H. M. Sandler, M. R. Sydes, B. Tombal, S. G. Williams, C. J. Sweeney and I. W. Group (2017). “Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.” J Clin Oncol 35(27): 3097-3104.
* Cancer Trials Ireland author listed in supplementary materials |
Study Number: Short Name |
2016 Journal Publications |
| 12-16: AC-ANGIOPREDICT | Betge, J., A. Barat, V. Murphy, T. Hielscher, N. C. Van Grieken, S. Belle, T. Zhan, N. Härtel, M. Kripp, O. Bacon, M. Cordes, E. W. Kay, H. M. Verheul, M. Neerincx, B. Hennessy, R. D. Hofheinz, T. Gaiser, B. Ylstra, J. H. Prehn, D. Lambrechts, A. T. Byrne, M. P. Ebert and N. Schulte (2016). “Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.” Digestion 94(3): 129-137. |
| 02-04: EORTC Prostate | Bolla, M., P. Maingon, C. Carrie, S. Villa, P. Kitsios, P. M. Poortmans, S. Sundar, E. M. van der Steen-Banasik, J. Armstrong, J. F. Bosset, F. G. Herrera, B. Pieters, A. Slot, A. Bahl, R. Ben-Yosef, D. Boehmer, C. Scrase, L. Renard, E. Shash, C. Coens, A. C. van den Bergh and L. Collette (2016). “Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.” J Clin Oncol 34(15): 1748-1756. |
| 08-18: CHHiP Study | Dearnaley, D., I. Syndikus, H. Mossop, V. Khoo, A. Birtle, D. Bloomfield, J. Graham, P. Kirkbride, J. Logue, Z. Malik, J. Money-Kyrle, J. M. O’Sullivan, M. Panades, C. Parker, H. Patterson, C. Scrase, J. Staffurth, A. Stockdale, J. Tremlett, M. Bidmead, H. Mayles, O. Naismith, C. South, A. Gao, C. Cruickshank, S. Hassan, J. Pugh, C. Griffin, E. Hall and C. H. Investigators (2016). “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.” Lancet Oncol 17(8): 1047-1060. |
| 09-01: TRIO 018 | Finn, R. S., J. P. Crown, J. Ettl, M. Schmidt, I. M. Bondarenko, I. Lang, T. Pinter, K. Boer, R. Patel, S. Randolph, S. T. Kim, X. Huang, P. Schnell, S. Nadanaciva, C. H. Bartlett and D. J. Slamon (2016). “Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.” Breast Cancer Res 18(1): 67. |
| 12-43: TRIO 022/ PALOMA-2 | Finn, R. S., M. Martin, H. S. Rugo, S. Jones, S. A. Im, K. Gelmon, N. Harbeck, O. N. Lipatov, J. M. Walshe, S. Moulder, E. Gauthier, D. R. Lu, S. Randolph, V. Dieras and D. J. Slamon (2016). “Palbociclib and Letrozole in Advanced Breast Cancer.” N Engl J Med 375(20): 1925-1936. |
| 05-09: IBIS-II | Forbes, J. F., I. Sestak, A. Howell, B. Bonanni, N. Bundred, C. Levy, G. von Minckwitz, W. Eiermann, P. Neven, M. Stierer, C. Holcombe, R. E. Coleman, L. Jones, I. Ellis, J. Cuzick and I.-I. investigators (2016). “Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.” Lancet 387(10021): 866-873. |
| 09-03: AGO-OVA 16 (GSK: VEG110655) | Harter, P., T. Johnson, D. Berton-Rigaud, S. Y. Park, M. Friedlander, J. M. Del Campo, M. Shimada, F. Forget, M. R. Mirza, N. Colombo, C. Zamagni, J. K. Chan, M. Imhof, T. J. Herzog, D. O’Donnell, F. Heitz, K. King, S. Stinnett, C. Barrett, M. Jobanputra, C. F. Xu and A. du Bois (2016). “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.” Gynecol Oncol 140(3): 443-449. |
| 01-04: BCIRG 005 | Press, M. F., G. Sauter, M. Buyse, H. Fourmanoir, E. Quinaux, D. D. Tsao-Wei, W. Eiermann, N. Robert, T. Pienkowski, J. Crown, M. Martin, V. Valero, J. R. Mackey, V. Bee, Y. Ma, I. Villalobos, A. Campeau, M. Mirlacher, M. A. Lindsay and D. J. Slamon (2016). “HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.” J Clin Oncol 34(29): 3518-3528. |
| 09-03: AGO-OVA 16 (GSK: VEG110655) | Pulford, D. J., P. Harter, A. Floquet, C. Barrett, D. H. Suh, M. Friedlander, J. A. Arranz, K. Hasegawa, H. Tada, P. Vuylsteke, M. R. Mirza, N. Donadello, G. Scambia, T. Johnson, C. Cox, J. K. Chan, M. Imhof, T. J. Herzog, P. Calvert, P. Wimberger, D. Berton-Rigaud, M. C. Lim, G. Elser, C. F. Xu and A. du Bois (2016). “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.” BMC Med Ethics 17(1): 63. |
| 14-13: MK3475-024/KEYNOTE-024 | Reck, M., D. Rodriguez-Abreu, A. G. Robinson, R. Hui, T. Csoszi, A. Fulop, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rangwala, J. R. Brahmer and K.-. Investigators (2016). “Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.” N Engl J Med 375(19): 1823-1833. |
| 06-02: SOFT | Regan, M. M., P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, G. Viale, M. Colleoni, I. Lang, H. L. Gomez, C. Tondini, G. Pinotti, K. N. Price, A. S. Coates, A. Goldhirsch and R. D. Gelber (2016). “Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.” J Clin Oncol 34(19): 2221-2231. |
| Scott, K., P. J. Hayden, A. Will, K. Wheatley and I. Coyne (2016). “Bortezomib for the treatment of multiple myeloma.” Cochrane Database Syst Rev 4: CD010816. | |
| 10-05: TCHL | Toomey, S., A. J. Eustace, L. B. Pritzker, K. P. Pritzker, J. Fay, A. O’Grady, R. Cummins, L. Grogan, J. Kennedy, D. O’Connor, L. Young, E. W. Kay, N. O’Donovan, W. M. Gallagher, R. Kalachand, J. Crown and B. T. Hennessy (2016). “RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” J Natl Cancer Inst 108(8). |
Study Number: Short Name |
2015 Journal Publications |
| 09-01: TRIO 018 | Finn, R. S., J. P. Crown, I. Lang, K. Boer, I. M. Bondarenko, S. O. Kulyk, J. Ettl, R. Patel, T. Pinter, M. Schmidt, Y. Shparyk, A. R. Thummala, N. L. Voytko, C. Fowst, X. Huang, S. T. Kim, S. Randolph and D. J. Slamon (2015). “The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.” Lancet Oncol 16(1): 25-35. |
| 09-03: AGO-OVA 16 (GSK: VEG110655) | Floquet, A., I. Vergote, N. Colombo, B. Fiane, B. J. Monk, A. Reinthaller, P. Calvert, T. J. Herzog, W. Meier, J. W. Kim, J. M. del Campo, M. Friedlander, C. Pisano, S. Isonishi, R. J. Crescenzo, C. Barrett, K. Wang, I. Mitrica and A. du Bois (2015). “Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.” Gynecol Oncol 136(1): 37-42. |
| 08-09: Patient Customised Headrest Study | Howlin, C., E. O’Shea, M. Dunne, L. Mullaney, M. McGarry, A. Clayton-Lea, M. Finn, P. Carter, B. Garret and P. Thirion (2015). “A randomized controlled trial comparing customized versus standard headrests for head and neck radiotherapy immobilization in terms of set-up errors, patient comfort and staff satisfaction (ICORG 08-09).” Radiography 21(1): 74-83. |
| 08-10: TC-Avastin | Sparano, J. A., R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain, D. F. Hayes, C. E. Geyer, Jr., E. C. Dees, E. A. Perez, J. A. Olson, Jr., J. Zujewski, T. Lively, S. S. Badve, T. J. Saphner, L. I. Wagner, T. J. Whelan, M. J. Ellis, S. Paik, W. C. Wood, P. Ravdin, M. M. Keane, H. L. Gomez Moreno, P. S. Reddy, T. F. Goggins, I. A. Mayer, A. M. Brufsky, D. L. Toppmeyer, V. G. Kaklamani, J. N. Atkins, J. L. Berenberg and G. W. Sledge (2015). “Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.” N Engl J Med 373(21): 2005-2014. |
| 06-15: Proteomic Prostate Study | Tonry, C. L., D. Doherty, C. O’Shea, B. Morrissey, L. Staunton, B. Flatley, A. Shannon, J. Armstrong and S. R. Pennington (2015). “Discovery and Longitudinal Evaluation of Candidate Protein Biomarkers for Disease Recurrence in Prostate Cancer.” J Proteome Res 14(7): 2769-2783. |
Study Number: Short Name |
2014 Journal Publications |
| 97-01: Prostate | Barry, A. S., M. T. Dunne, C. A. Lyons, M. A. Finn, B. Moulton, J. C. Taylor, C. M. O’Shea, P. G. Thirion and J. G. Armstrong (2014). “Temporal patterns of late bowel and bladder radiotherapy toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones in prostate cancer.” Acta Oncol 53(10): 1390-1397. |
| 05-09: IBIS-II | Cuzick, J., I. Sestak, J. F. Forbes, M. Dowsett, J. Knox, S. Cawthorn, C. Saunders, N. Roche, R. E. Mansel, G. von Minckwitz, B. Bonanni, T. Palva, A. Howell and I.-I. investigators (2014). “Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.” Lancet 383(9922): 1041-1048. |
| 05-04: Bladder-Filling Prostate Study | Mullaney, L. M., E. O’Shea, M. T. Dunne, M. A. Finn, P. G. Thirion, L. A. Cleary, M. McGarry, L. O’Neill and J. G. Armstrong (2014). “A randomized trial comparing bladder volume consistency during fractionated prostate radiation therapy.” Pract Radiat Oncol 4(5): e203-212. |
Study Number: Short Name |
2013 Journal Publications |
| 08-20: BMS CA180227 (READY) Study: Taxotere+/- Dasatinib in Hormone Refractory Prostate Cancer | Araujo, J. C., G. C. Trudel, F. Saad, A. J. Armstrong, E. Y. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, S. V. Serrano, V. B. Matveev, E. Efstathiou, S. Oudard, M. J. Morris, B. Sizer, P. J. Goebell, A. Heidenreich, J. S. de Bono, S. Begbie, J. H. Hong, E. Richardet, E. Gallardo, P. Paliwal, S. Durham, S. Cheng and C. J. Logothetis (2013). “Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.” Lancet Oncol 14(13): 1307-1316. |
| 01-03: BCIRG 006 | Au, H. J., W. Eiermann, N. J. Robert, T. Pienkowski, J. Crown, M. Martin, M. Pawlicki, A. Chan, J. Mackey, J. Glaspy, T. Pinter, M. C. Liu, T. Fornander, S. Sehdev, J. M. Ferrero, V. Bee, M. J. Santana, D. P. Miller, D. Lalla, D. J. Slamon and B. T. I. Translational Research in Oncology (2013). “Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.” Oncologist 18(7): 812-818. |
| 05-10: Velcade Meso | Busacca, S., A. D. Chacko, A. Klabatsa, K. Arthur, M. Sheaff, D. Barbone, L. Mutti, V. K. Gunasekharan, J. J. Gorski, M. El-Tanani, V. C. Broaddus, G. Gaudino and D. A. Fennell (2013). “BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.” PLoS One 8(6): e65489. |
| 06-04: EGF100161 | Crown, J., M. J. Kennedy, P. Tresca, M. Marty, M. Espie, H. A. Burris, M. DeSilvio, M. R. Lau, D. Kothari, K. M. Koch and V. Dieras (2013). “Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.” Ann Oncol 24(8): 2005-2011. |
| 07-08: A6181099 | Crown, J. P., V. Dieras, E. Staroslawska, D. A. Yardley, T. Bachelot, N. Davidson, H. Wildiers, P. A. Fasching, O. Capitain, M. Ramos, R. Greil, F. Cognetti, G. Fountzilas, M. Blasinska-Morawiec, C. Liedtke, R. Kreienberg, W. H. Miller, Jr., V. Tassell, X. Huang, J. Paolini, K. A. Kern and G. Romieu (2013). “Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.” J Clin Oncol 31(23): 2870-2878. |
| 06-14: Prosty | Kellokumpu-Lehtinen, P. L., U. Harmenberg, T. Joensuu, R. McDermott, P. Hervonen, C. Ginman, M. Luukkaa, P. Nyandoto, A. Hemminki, S. Nilsson, J. McCaffrey, R. Asola, T. Turpeenniemi-Hujanen, F. Laestadius, T. Tasmuth, K. Sandberg, M. Keane, I. Lehtinen, T. Luukkaala, H. Joensuu and P. s. group (2013). “2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.” Lancet Oncol 14(2): 117-124. |
| 98-01: BIG 2-98 | Loi, S., N. Sirtaine, F. Piette, R. Salgado, G. Viale, F. Van Eenoo, G. Rouas, P. Francis, J. P. Crown, E. Hitre, E. de Azambuja, E. Quinaux, A. Di Leo, S. Michiels, M. J. Piccart and C. Sotiriou (2013). “Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.” J Clin Oncol 31(7): 860-867. |
| 06-15: Proteomic Prostate Study | Morrissey, B., C. O’Shea, J. Armstrong, C. Rooney, L. Staunton, M. Sheehan, A. M. Shannon and S. R. Pennington (2013). “Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.” Proteomics Clin Appl 7(5-6): 316-326. |
| 97-01: Prostate | Mydin, A. R., M. T. Dunne, M. A. Finn and J. G. Armstrong (2013). “Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy–a secondary analysis of irish clinical oncology research group 97-01.” Int J Radiat Oncol Biol Phys 85(1): 101-108. |
| 98-01: BIG 2-98 | Oakman, C., P. A. Francis, J. Crown, E. Quinaux, M. Buyse, E. De Azambuja, M. Margeli Vila, M. Andersson, B. Nordenskjold, R. Jakesz, B. Thurlimann, J. Gutierrez, V. Harvey, L. Punzalan, P. Dell’orto, D. Larsimont, I. Steinberg, R. D. Gelber, M. Piccart-Gebhart, G. Viale and A. Di Leo (2013). “Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer–8-year results of the Breast International Group 02-98 phase III trial.” Ann Oncol 24(5): 1203-1211. |
| 05-02: NSABP C08 | Pogue-Geile, K., G. Yothers, Y. Taniyama, N. Tanaka, P. Gavin, L. Colangelo, N. Blackmon, C. Lipchik, S. R. Kim, S. Sharif, C. Allegra, N. Petrelli, M. J. O’Connell, N. Wolmark and S. Paik (2013). “Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.” J Natl Cancer Inst 105(13): 989-992. |
| 10-18: A8081007 | Shaw, A. T., D. W. Kim, K. Nakagawa, T. Seto, L. Crino, M. J. Ahn, T. De Pas, B. Besse, B. J. Solomon, F. Blackhall, Y. L. Wu, M. Thomas, K. J. O’Byrne, D. Moro-Sibilot, D. R. Camidge, T. Mok, V. Hirsh, G. J. Riely, S. Iyer, V. Tassell, A. Polli, K. D. Wilner and P. A. Janne (2013). “Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.” N Engl J Med 368(25): 2385-2394. |
| 05-11: NSABP B38 | Swain, S. M., G. Tang, C. E. Geyer, Jr., P. Rastogi, J. N. Atkins, P. P. Donnellan, L. Fehrenbacher, C. A. Azar, A. Robidoux, J. A. Polikoff, A. M. Brufsky, D. D. Biggs, E. A. Levine, J. L. Zapas, L. Provencher, D. W. Northfelt, S. Paik, J. P. Costantino, E. P. Mamounas and N. Wolmark (2013). “Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.” J Clin Oncol 31(26): 3197-3204. |
Study Number: Short Name |
2012 Journal Publications |
| 06-22: Trastuzumab Biomarker Study | Browne, B. C., A. J. Eustace, S. Kennedy, N. A. O’Brien, K. Pedersen, M. S. McDermott, A. Larkin, J. Ballot, T. Mahgoub, F. Sclafani, S. Madden, J. Kennedy, M. J. Duffy, J. Crown and N. O’Donovan (2012). “Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.” Breast Cancer Res Treat 136(3): 717-727. |
| 08-08: Biomarkers of Response to Taxotere in HRPC | Corcoran, C., S. Rani, K. O’Brien, A. O’Neill, M. Prencipe, R. Sheikh, G. Webb, R. McDermott, W. Watson, J. Crown and L. O’Driscoll (2012). “Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.” PLoS One 7(12): e50999. |
| 97-01: Prostate | Daly, P. E., M. T. Dunne, C. M. O’Shea, M. A. Finn and J. G. Armstrong (2012). “The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01).” Radiother Oncol 104(1): 96-102. |
| 07-12: Collaborative Biomarker Study | Dowling, P., C. Clarke, K. Hennessy, B. Torralbo-Lopez, J. Ballot, J. Crown, I. Kiernan, K. J. O’Byrne, M. J. Kennedy, V. Lynch and M. Clynes (2012). “Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.” Int J Cancer 131(4): 911-923. |
| 05-10: Velcade Meso | Fennell, D. A., C. McDowell, S. Busacca, G. Webb, B. Moulton, A. Cakana, K. J. O’Byrne, J. V. Meerbeeck, P. Donnellan, J. McCaffrey and P. Baas (2012). “Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.” J Thorac Oncol 7(9): 1466-1470. |
| 08-21: Cougar Phase III Study COU-AA-301 | Fizazi, K., H. I. Scher, A. Molina, C. J. Logothetis, K. N. Chi, R. J. Jones, J. N. Staffurth, S. North, N. J. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O. B. Goodman, Jr., C. N. Sternberg, J. H. Li, T. Kheoh, C. M. Haqq, J. S. de Bono and C.-A.-. Investigators (2012). “Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.” Lancet Oncol 13(10): 983-992. |
Study Number: Short Name |
2011 Journal Publications |
| 06-07: Coin | Adams, R. A., A. M. Meade, M. T. Seymour, R. H. Wilson, A. Madi, D. Fisher, S. L. Kenny, E. Kay, E. Hodgkinson, M. Pope, P. Rogers, H. Wasan, S. Falk, S. Gollins, T. Hickish, E. M. Bessell, D. Propper, M. J. Kennedy, R. Kaplan, T. S. Maughan and M. C. T. Investigators (2011). “Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.” Lancet Oncol 12(7): 642-653. |
| 05-02: NSABP C08 | Allegra, C. J., G. Yothers, M. J. O’Connell, S. Sharif, N. J. Petrelli, L. H. Colangelo, J. N. Atkins, T. E. Seay, L. Fehrenbacher, R. M. Goldberg, S. O’Reilly, L. Chu, C. A. Azar, S. Lopa and N. Wolmark (2011). “Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.” J Clin Oncol 29(1): 11-16. |
| 97-01: Prostate | Armstrong, J. G., C. M. Gillham, M. T. Dunne, D. A. Fitzpatrick, M. A. Finn, M. E. Cannon, J. C. Taylor, C. M. O’Shea, S. J. Buckney and P. G. Thirion (2011). “A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.” Int J Radiat Oncol Biol Phys 81(1): 35-45. |
| 04-01: AZURE | Coleman, R., E. Woodward, J. Brown, D. Cameron, R. Bell, D. Dodwell, M. Keane, M. Gil, C. Davies, R. Burkinshaw, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee and H. Thorpe (2011). “Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.” Breast Cancer Res Treat 127(2): 429-438. |
| 04-01: AZURE | Coleman, R. E., H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, M. Gil, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee, D. Ritchie, J. Pugh, C. Gaunt, U. Rea, J. Peterson, C. Davies, V. Hiley, W. Gregory, R. Bell and A. Investigators (2011). “Breast-cancer adjuvant therapy with zoledronic acid.” N Engl J Med 365(15): 1396-1405. |
| 97-01: Prostate | D’Amico, A. V., M. H. Chen, J. Crook, J. G. Armstrong, S. Malone, A. Steigler, M. Dunne, P. W. Kantoff and J. W. Denham (2011). “Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.” J Clin Oncol 29(35): 4682-4687. |
| 01-04: BCIRG 005 | Eiermann, W., T. Pienkowski, J. Crown, S. Sadeghi, M. Martin, A. Chan, M. Saleh, S. Sehdev, L. Provencher, V. Semiglazov, M. Press, G. Sauter, M. A. Lindsay, A. Riva, M. Buyse, P. Drevot, H. Taupin and J. R. Mackey (2011). “Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.” J Clin Oncol 29(29): 3877-3884. |
| 97-01: Prostate | Fleming, C., C. Kelly, P. Thirion, K. Fitzpatrick and J. Armstrong (2011). “A method for the prediction of late organ-at-risk toxicity after radiotherapy of the prostate using equivalent uniform dose.” Int J Radiat Oncol Biol Phys 80(2): 608-613. |
| 06-06: CIRG TORI 010 | Martin, M., H. Roche, T. Pinter, J. Crown, M. J. Kennedy, L. Provencher, F. Priou, W. Eiermann, E. Adrover, I. Lang, M. Ramos, J. Latreille, A. Jagiello-Gruszfeld, T. Pienkowski, E. Alba, R. Snyder, S. Almel, J. Rolski, M. Munoz, R. Moroose, S. Hurvitz, A. Banos, H. Adewoye, Y. J. Hei, M. A. Lindsay, M. Rupin, D. Cabaribere, Y. Lemmerick, J. R. Mackey and T. investigators (2011). “Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.” Lancet Oncol 12(4): 369-376. |
| 01-03: BCIRG 006 | Slamon, D., W. Eiermann, N. Robert, T. Pienkowski, M. Martin, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pinter, V. Valero, M. C. Liu, G. Sauter, G. von Minckwitz, F. Visco, V. Bee, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. A. Lindsay, A. Riva, J. Crown and G. Breast Cancer International Research (2011). “Adjuvant trastuzumab in HER2-positive breast cancer.” N Engl J Med 365(14): 1273-1283. |
| 01-09: BCIRG 007 | Valero, V., J. Forbes, M. D. Pegram, T. Pienkowski, W. Eiermann, G. von Minckwitz, H. Roche, M. Martin, J. Crown, J. R. Mackey, P. Fumoleau, J. Rolski, Z. Mrsic-Krmpotic, A. Jagiello-Gruszfeld, A. Riva, M. Buyse, H. Taupin, G. Sauter, M. F. Press and D. J. Slamon (2011). “Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.” J Clin Oncol 29(2): 149-156. |
Study Number: Short Name |
2010 Journal Publications |
| 99-09: 3DCRT Lung | Brennan, S. M., P. Thirion, S. Buckney, C. O. Shea and J. Armstrong (2010). “Factors influencing conformity index in radiotherapy for non-small cell lung cancer.” Med Dosim 35(1): 38-42. |
| 04-01: AZURE | Coleman, R. E., M. C. Winter, D. Cameron, R. Bell, D. Dodwell, M. M. Keane, M. Gil, D. Ritchie, J. L. Passos-Coelho, D. Wheatley, R. Burkinshaw, S. J. Marshall, H. Thorpe and A. Investigators (2010). “The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.” Br J Cancer 102(7): 1099-1105. |
| 97-02: ACCOG-1 | Mansi, J. L., A. Yellowlees, J. Lipscombe, H. M. Earl, D. A. Cameron, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, J. Crown, A. L. Jones, M. Highley, R. C. Leonard and T. R. Evans (2010). “Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.” Breast Cancer Res Treat 122(3): 787-794. |
Study Number: Short Name |
2009 Journal Publications |
| 05-02: NSABP C08 | Allegra, C. J., G. Yothers, M. J. O’Connell, S. Sharif, L. H. Colangelo, S. H. Lopa, N. J. Petrelli, R. M. Goldberg, J. N. Atkins, T. E. Seay, L. Fehrenbacher, S. O’Reilly, L. Chu, C. A. Azar and N. Wolmark (2009). “Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.” J Clin Oncol 27(20): 3385-3390. |
| 04-09: EGF30008 | Johnston, S., J. Pippen, Jr., X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, M. F. Press, J. Maltzman, A. Florance, L. O’Rourke, C. Oliva, S. Stein and M. Pegram (2009). “Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.” J Clin Oncol 27(33): 5538-5546. |
Study Number: Short Name |
2008 Journal Publications |
| 04-08: EGF100151 | Cameron, D., M. Casey, M. Press, D. Lindquist, T. Pienkowski, C. G. Romieu, S. Chan, A. Jagiello-Gruszfeld, B. Kaufman, J. Crown, A. Chan, M. Campone, P. Viens, N. Davidson, V. Gorbounova, J. I. Raats, D. Skarlos, B. Newstat, D. Roychowdhury, P. Paoletti, C. Oliva, S. Rubin, S. Stein and C. E. Geyer (2008). “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.” Breast Cancer Res Treat 112(3): 533-543. |
| 98-01: BIG 2-98 | Francis, P., J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, J. Gutierrez, G. van Hazel, S. Dolci, S. Jamin, B. Bendahmane, R. D. Gelber, A. Goldhirsch, M. Castiglione-Gertsch, M. Piccart-Gebhart and B. I. G. C. Group (2008). “Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.” J Natl Cancer Inst 100(2): 121-133. |
| 98-01: BIG 2-98 | Pestalozzi, B. C., P. Francis, E. Quinaux, S. Dolci, E. Azambuja, R. D. Gelber, G. Viale, A. Balil, M. Andersson, B. Nordenskjold, M. Gnant, J. Gutierrez, I. Lang, J. P. Crown, M. Piccart-Gebhart and B. I. G. C. Group (2008). “Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.” Ann Oncol 19(11): 1837-1841. |
Study Number: Short Name |
2007 Journal Publications |
| 06-03: Epi Sulindac | O’Connor, R., M. O’Leary, J. Ballot, C. D. Collins, P. Kinsella, D. E. Mager, R. D. Arnold, L. O’Driscoll, A. Larkin, S. Kennedy, D. Fennelly, M. Clynes and J. Crown (2007). “A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.” Cancer Chemother Pharmacol 59(1): 79-87. |
Study Number: Short Name |
2006 Journal Publications |
| 00-01: Epilymph | Besson, H., P. Brennan, N. Becker, A. Nieters, S. De Sanjose, R. Font, M. Maynadie, L. Foretova, P. L. Cocco, A. Staines, M. Vornanen and P. Boffetta (2006). “Tobacco smoking, alcohol drinking and non-Hodgkin’s lymphoma: A European multicenter case-control study (Epilymph).” Int J Cancer 119(4): 901-908. |
| 04-08: EGF100151 | Geyer, C. E., J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein and D. Cameron (2006). “Lapatinib plus capecitabine for HER2-positive advanced breast cancer.” N Engl J Med 355(26): 2733-2743. |
Study Number: Short Name |
2004 Journal Publications |
| 97-02: ACCOG-1 | Leonard, R. C., M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, M. Verrill, D. Cameron, E. Foster, A. Yellowlees, J. Crown and G. Anglo-Celtic Cooperative Oncology (2004). “Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.” J Natl Cancer Inst 96(14): 1076-1083. |
Study Number: Short Name |
2002 Journal Publications |
| 97-02: ACCOG-1 | Cameron, D. A., A. Anderson, E. Toy, T. R. Evans, J. H. Le Vay, I. C. Kennedy, R. J. Grieve, T. J. Perren, A. Jones, J. Mansi, J. Crown and R. C. Leonard (2002). “Block sequential adriamycin CMF–optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?” Br J Cancer 87(12): 1365-1369. |